Cat Stago International en - BD Eb

Haemostasis Catalogue
2013
iPad is a trademark of Apple Inc., registered in the U.S. and other countries
Summary
Systems
STA-R Evolution Expert Series System ....................................................................................................................................................................6

STA Compact Max System.......................................................................................................................................................................................7
STA Compact System ..............................................................................................................................................................................................8
STA Compact CT System .........................................................................................................................................................................................9
STA Satellite System..............................................................................................................................................................................................10
STart4 System .......................................................................................................................................................................................................11
CAT System..............................................................................................................................................................................................................12
STA Coag Connexion System .................................................................................................................................................................................13
Reagents
15
Screening Tests
17
Prothrombin Time....................................................................................................................................................................................................18
APTT ........................................................................................................................................................................................................................19
Fibrinogen ...............................................................................................................................................................................................................20
Thrombin Time ..............................................................................................................................................................................21
Factor Assays
23
Decient Plasmas ....................................................................................................................................................................................................24

Other Techniques .....................................................................................................................................................................................................25
Fibrin Formation & Degradation
27
Fibrin Formation ......................................................................................................................................................................................................28

Degradation products ..............................................................................................................................................................................................29
Fibrinolysis
31
Fibrinolysis...............................................................................................................................................................................................................32
Anticoagulant Treatments
33
Heparins & Direct Anti-Xa ........................................................................................................................................................................................34

Direct Thrombin Inhibitors .......................................................................................................................................................................................36
Thrombophilia
37
Antithrombin & Protein C.........................................................................................................................................................................................38

Protein S & C4b-Binding Protein ............................................................................................................................................................................39
Others Inhibitors ......................................................................................................................................................................................................40
Lupus Anticoagulant (LA) ........................................................................................................................................................................................41
Antiphospholipid Antibodies (APA) ..........................................................................................................................................................................42
Primary Haemostasis
43
Von Willebrand Factor & Activation Markers ...........................................................................................................................................................44

Platelets...................................................................................................................................................................................................................45
Monoclonal Antibodies For Flow Cytometry ...........................................................................................................................................................46
Calibrators & Controls
49
Calibration Plasmas .................................................................................................................................................................................................50

Control Plasmas ......................................................................................................................................................................................................51
Auxiliary Reagents
53
Auxiliary Reagents ...................................................................................................................................................................................................54
Research Products
55
Research Kits ...........................................................................................................................................................................................................57

Puried Proteins ......................................................................................................................................................................................................58
Chromogenic Substrates & Activators ......................................................................................................................................................................59
Monoclonal Antibodies For Flow Cytometry ...........................................................................................................................................................60
Thrombin Generation (CAT).....................................................................................................................................................................................62
Disposables & Auxiliary materials
63
STA-R / STA-R Evolution Expert Series Disposables ...........................................................................................................................................64

STA-R / STA-R Evolution Expert Series Disposables Spare Parts ........................................................................................................................65
STA-R / STA-R Evolution Expert Series Auxiliary Materials .................................................................................................................................66
STA Compact Max /STA Compact USB & STA Compact CT USB Disposables...................................................................................................67
STA Compact Max /STA Compact USB & STA Compact CT USB Disposable Spare Parts .................................................................................68
STA Compact Max /STA Compact USB & STA Compact CT USB Auxiliary Materials ........................................................................................69
STA Satellite Disposables ......................................................................................................................................................................................70
STA Satellite Auxiliary Materials ............................................................................................................................................................................71
Semi-Automated Analysers Disposables ................................................................................................................................................................72
Semi-Automated Analysers Auxiliary Materials ......................................................................................................................................................73
CAT Disposables ......................................................................................................................................................................................................74
Index
75
The information contained in this catalogue are not contractual

and can be modified at any time.
This catalogue is not intended for use in the USA and Canada.
Systems
Systems
This catalogue contains information on products which is targeted
to a wide range of audiences and could contain product details or
information otherwise not accessible or valid in your country.
STA-R Evolution Expert Series System

/DVWUHOHDVHGRIWKH67$5OLQHWKH67$5(YROXWLRQ([SHUW
6HULHVFRPELQHVSHUIRUPDQFHXVHUIULHQGOLQHVVDQGVHFXULW\
6WDQGDORQHRUFRQQHFWHGWRDQDXWRPDWHGURERWLFOLQHLWIHDWXUHV
WKHODWHVWWHFKQRORJLFDOLQQRYDWLRQV
$QHZ:LQGRZV;3 EDVHGVRIWZDUHLQWHJUDWLQJPRUHH[LELOLW\XVHUIULHQGOLQHVVWUDFHDELOLW\
DQGVHFXULW\IRUDEHWWHUHIIHFWLYHQHVV
$QRSWLPDOVDPSOHPDQDJHPHQWKLJKZRUNRZFRQWLQXRXVORDGLQJDQGXQORDGLQJSURFHGXUHV
ODUJHRQERDUGFDSDFLW\FRROHGVDPSOHDUHD
'HGLFDWHGDFFUHGLWDWLRQDQGFHUWLFDWLRQIHDWXUHVFRPSOHWHDQGVHFXUHWUDFHDELOLW\OHDQG
GLIIHUHQWGDWDH[SRUWIRUPDWV
7KHPRVWH[LEOHVROXWLRQWRLQWHUIDFHFRDJXODWLRQZLWKDXWRPDWHGURERWLFOLQHV
+LJKTXDOLW\UHVXOWVYLVFRVLW\EDVHGGHWHFWLRQV\VWHP
-.//0 1
2
UDFNVVDPSOHWUD\V
FDEOHV
DX[LOLDU\PDWHULDOFDVH
/&'WRXFKVFUHHQ
$=(57<RU4:(57<NH\ERDUGZLWKWRXFKSDG

37
$377
)LEULQRJHQ
7KURPELQ7LPH
([WULQVLFSDWKZD\IDFWRUV
,QWULQVLFSDWKZD\IDFWRUV
/XSXV$QWLFRDJXODQW
9:)
0LFURSDUWLFOHV
3ODVPLQRJHQ$QWLSODVPLQDQG7$),
&DOLEUDWRUV
4XDOLW\&RQWURO
$QWL;D
''LPHUV )LEULQ0RQRPHUV
$QWLWKURPELQ
3URWHLQ&
$FWLYDWHG3URWHLQ&5HVLVWDQFH
3URWHLQ6

"%*+
67$5(YROXWLRQ([SHUW6HULHV
!" #$
"%*+
67$5(YROXWLRQ([SHUW6HULHVHTXLSSHGZLWKFDSSLHUFLQJ
"%&"%
"%
"%&"'
"% &++
++
() &&"!* #$
() !* #$
"%&*
"%&,%
"%&*
"%&,,
() !" #$

"%&"&
"%&"
6\VWHPV
)RU8QLWHG.LQJGRPRQO\
)RU$XVWUDOLD1HZ=HDODQGRQO\
:LQGRZV;3LVDWUDGHPDUNRI0LFURVRIW&RUSRUDWLRQ
STA Compact Max System

1HZERUQRIWKH67$IDPLO\WKH67$&RPSDFW0D[LVDEHQFK
WRSDQDO\]HUGHVLJQHGIRUPLGYROXPHWKURXJKSXWODERUDWRULHVDQG
VXLWDEOHIRUXVHLQURXWLQH VSHFLDOW\+HPRVWDVLVWHVWLQJ
7KHZRUNVWDWLRQHUJRQRPLFVDQGH[SHUWLVHRQERDUGHQKDQFH
HIILFLHQF\DQGSURGXFWLYLW\RIWKHODEDQGDOORZDVHDPOHVV
LQWHJUDWLRQIRUWKHVWDII
*UDSKLFDOXVHULQWHUIDFHVSHFLFDOO\GHVLJQHGIRULQWXLWLYHXVHRIWKHKLJKUHVROXWLRQWRXFKVFUHHQ
$GGLWLRQDOH[SHUWPRGXOHDXWRYHULFDWLRQUXOHVDXWRPDWLFPDQDJHPHQWRIGLOXWLRQVUHUXQVUHH[
WHVWLQJDQGDGGRQVDGYDQFHGTXDOLW\FRQWUROPRGXOHPXOWLGLOXWLRQPDQDJHPHQWIRUIDFWRUDVVD\VHWF
+LJKWUDFHDELOLW\FRPSOHWHPDQDJHPHQWRIUHDJHQWVHQWLUHSDWLHQWUHVXOWVDUFKLYLQJDQG
PDQDJHPHQWRIPDLQWHQDQFHE\VRIWZDUH
([WHQGHGVDPSOHUHDJHQWDQGGLVSRVDEOHORDGLQJFDSDFLWLHV
7UXH67$7PDQDJHPHQWZLWKRXWLPSDFWRQWKHLQVWUXPHQWWKURXJKSXW
2SHUDWRUVHFXULW\DQGVDIHW\ZLWKFDSSLHUFLQJRSWLRQDODQGSRVLWLYHLGHQWLFDWLRQRIVDPSOHVDQG
UHDJHQWV
&RPSUHKHQVLYHPHQXRIWHVWVDQGSUHFDOLEUDWLRQIRUORWVRIUHDJHQWV
9LVFRVLW\%DVHG0HFKDQLFDO'HWHFWLRQ6\VWHPLPPHGLDWHGHOLYHU\RIDFFXUDWHDQGSUHFLVH
UHVXOWVIRUDQ\W\SHRIFRORXUHGSODVPDDVVD\VPD[LPXPSUHFLVLRQIRUZHDNFORWGHWHFWLRQDQG
VWDQGDUGLVDWLRQEHWZHHQ6WDJRV\VWHPV
-.//0 1
2
&DEOHV
/&'VFUHHQ
$=(57<RU4:(57<NH\ERDUG
([SHUW0RGXOHRSWLRQDO

37
$377
)LEULQRJHQ
7KURPELQ7LPH
$QWL;D
$QWLWKURPELQ
3URWHLQ&
3URWHLQ6
9:)
/XSXV$QWLFRDJXODQW
0LFURSDUWLFOHV
&DOLEUDWRUV
4XDOLW\FRQWURO

() &&"3 !
&&"3 !
"%,&
67$&RPSDFW0D[4:(57<
"%, '
67$&RPSDFW0D[$=(57<
"%,&
67$&RPSDFW0D[4:(57<&DS3LHUFLQJ
"%,&
67$&RPSDFW0D[$=(57<&DS3LHUFLQJ
"%,
67$&RPSDFW0D[4:(57<([SHUW0RGXOH
"%,'
67$&RPSDFW0D[$=(57<([SHUW0RGXOH
"%,
67$&RPSDFW0D[4:(57<&DS3LHUFLQJ([SHUW0RGXOH
"%,
67$&RPSDFW0D[$=(57<&DS3LHUFLQJ([SHUW0RGXOH
6\VWHPV
STA Compact USB System

67$&RPSDFW86%LVDIXOO\DXWRPDWHGEHQFKWRS+DHPRVWDVLV
DQDO\VHUSHUIRUPLQJFORWWLQJFKURPRJHQLFDQGLPPXQRORJLFDO
DVVD\VLQDUDQGRPDFFHVVPRGHGHVLJQHGIRUPLGYROXPH
WKURXJKSXWODERUDWRULHV
3URYHQSODWIRUPZLWKH[WHQGHGSUHVHQFHZRUOGZLGHRYHUPRUHWKDQFRXQWULHV
&RQWLQXRXVVDPSOHORDGLQJDQG67$7PDQDJHPHQW
2SWLPDOVHFXULW\ZLWKWKHRSWLRQDOFDSSLHUFLQJGHYLFH
%DUFRGHGUHDJHQWOLQHFRPSOHWHPDQDJHPHQWRI3URGXFW,QIRUPDWLRQ
-.//0 1
2
&DEOHV
/&'VFUHHQ

37
$377
)LEULQRJHQ
7KURPELQ7LPH
$QWL;D
$QWLWKURPELQ
3URWHLQ&
3URWHLQ6
9:)
/XSXV$QWLFRDJXODQW
0LFURSDUWLFOHV
&DOLEUDWRUV
4XDOLW\FRQWURO

&&"3 !

"%*&
67$&RPSDFW86%
"%*
67$&RPSDFW86%HTXLSSHGZLWKFDSSLHUFLQJ
() &&"3 !

"%*'
67$&RPSDFW86%
"%*
"%*" +
67$&RPSDFW86%
"%* +
"%* *++
67$&RPSDFW86%
"%*&*++
6\VWHPV
)RU&KLQDRQO\
STA Compact CT USB System

67$&RPSDFW&786%LVVSHFLILFDOO\GHVLJQHGIRUFORWWLQJDVVD\V
DQGDOORZVWRHYHU\ODERUDWRU\WRDFFHVVDXWRPDWLRQDQGRSWLPLVH
LWVZRUNIORZ
-.//0 1
2
&RQWLQXRXVVDPSOHORDGLQJDQG67$7PDQDJHPHQW
2SWLPDOVHFXULW\ZLWKWKHRSWLPDOFDSSLHUFLQJGHYLFH
+LJKWTXDOLW\UHVXOWVYLVFRVLW\EDVHGGHWHFWLRQV\VWHP
&DEOHV
/&'VFUHHQ

37
$377
)LEULQRJHQ
7KURPELQ7LPH
,QWULQVLQFSDWKZD\IDFWRUV
$QWL;D
3URWHLQ&
3URWHLQ6
/XSXV$QWLFRDJXODQW
0LFURSDUWLFOHV
&DOLEUDWRUV
4XDOLW\&RQWUROV

&&"3 !

"%*&
67$&RPSDFW&786%
() &&"3 !

"%*
67$&RPSDFW&786%
"%*&+
67$&RPSDFW&786%
6\VWHPV
'
STA Satellite System

67$6DWHOOLWHLVDIXOO\DXWRPDWHG+DHPRVWDVLVDQDO\VHU
SHUIRUPLQJFORWWLQJFKURPRJHQLFDQGLPPXQRORJLFDODVVD\VLQD
UDQGRPDFFHVVPRGH
67$6DWHOOLWHRIIHUVFRPSOHWHDXWRPDWLRQWRORZPHGLXP
FRDJXODWLRQODERUDWRU\
7KDQNVWRLWVWHFKQRORJLFDOLQQRYDWLRQV67$6DWHOOLWHHQVXUHVD
KLJKUHOLDELOLW\OHYHODVZHOODVHDVHRIXVHIOH[LELOLW\DQGFRPSOHWH
VHFXULW\DOOZLWKLQDUHGXFHGIRRWSULQW
-.//0 1
2
([FHOOHQWLQWUD LQWHUDVVD\UHSURGXFLELOLW\RZLQJWR6WDJRSLSHWLQJGHYLFH
3RVLWLYHEDUFRGHLGHQWLFDWLRQRIVDPSOHVDQGUHDJHQWV
&RQWLQXRXVVDPSOHORDGLQJ
67$7VDPSOHPDQDJHPHQW
0LQLPDOXVHUPDLQWHQDQFH
,QWHJUDWHGTXDOLW\FRQWUROSURJUDP
+LJKWTXDOLW\UHVXOWVYLVFRVLW\EDVHGGHWHFWLRQV\VWHP
$OODFFHVVRULHVUHTXLUHG

$QWL;D
$QWLWKURPELQ
&DOLEUDWRUV
4XDOLW\FRQWURO
37
$377
)LEULQRJHQ
7KURPELQ7LPH
''LPHUV

"%&& +
67$6DWHOOLWH
"% &++
67$6DWHOOLWH
&
6\VWHPV
)RU$XVWUDOLDDQG1HZ=HDODQGFRXQWULHVRQO\
$YDLODELOLW\GHSHQGLQJXSRQWKHFRXQWU\
STart 4 System
6HPLDXWRPDWHGFRDJXODWLRQDQDO\VHU67DUWLVGHVLJQHGIRUDOOFORWWLQJWHVWV
&RPSDFWDQGXVHUIULHQGO\LWRIIHUVDQH[FHOOHQWUHOLDELOLW\WKDQNVWRWKH6WDJR
FORWGHWHFWLRQV\VWHP
3URYHQUHOLDELOLW\LQPRUHWKDQFRXQWULHV
$OOLQWHJUDWHGV\VWHPSULQWHUHOHFWURQLFDOO\OLQNHGSLSHWWRU/&'VFUHHQDQGNH\ERDUG
(DV\WRXVHSUHSURJUDPPHGDSSOLFDWLRQVFDOLEUDWLRQFXUYHVWRUDJHPDQDJHPHQWRI4XDOLW\
&RQWURODQGUHDJHQWVORWQXPEHUV
-.//0 1
2
$OODFFHVVRULHVUHTXLUHG

37
$377
)LEULQRJHQ
7KURPELQ7LPH
5HSWLODVH7LPH
$QWL;D
3URWHLQ&
3URWHLQ6
/XSXV$QWLFRDJXODQW
&DOLEUDWRUV
4XDOLW\FRQWURO

"%&&
67DUW99
6\VWHPV
&&
CAT System
&$7 LVDFRPSUHKHQVLYHV\VWHPWRPHDVXUH7KURPELQJHQHUDWLRQ
EDVHGRQIOXRUHVFHQFHDFFRUGLQJWRWKH+HPNHUHWDOPHWKRG
5HVHDUFKSURGXFW
)OXURUHVFHQFHDOORZVWKHXVHRI333RU353&DOLEUDWRUSODVPD
PDNHVWKHTXDQWLWDWLRQRIWKURPELQJHQHUDWHGSRVVLEOH,WDOVR
FRUUHFWVWKHVLJQDOIURPFRORXURISODVPDLQQHUILOWHUHIIHFWDQG
VXEVWUDWHGHSOHWLRQ
7KHGHGLFDWHGVRIWZDUHFDOFXODWHVLQUHDOWLPHDOOWKHUHOHYDQWSDUDPHWHUVOLNH(73
(QGRJHQRXV7KURPELQ3RWHQWLDOODJWLPHWLPHWRSHDNSHDNDQGPD[LPDOYHORFLW\RIWKURPELQ
JHQHUDWLRQ
5HDG\WRXVHVWDQGDUGLVHGUHDJHQWVH[SORUHGLIIHUHQWFRPSRQHQWVRIWKURPELQJHQHUDWLRQ
SODVPDWLFSODWHOHWVPLFURSDUWLFOHVDQWLWKURPELFGUXJVDQGDQWLSODWHOHWGUXJV
-.//0 1
2
H[FLWDWLRQOWHUQ0
HPLVVLRQOWHUQ0
7KURPELQRVFRSHVRIWZDUHGHGLFDWHGWRWKURPELQ
JHQHUDWLRQPHDVXUHPHQW
XVHUJXLGH
86%DVK
'HOO3&

7KURPELQ&DOLEUDWRU
3535HDJHQW
035HDJHQW
3335HDJHQW
3335HDJHQW/2:
3335HDJHQW+,*+
)OX&D.LW

%*&%'+
&$76\VWHP4:(57<
%*&%%+
&$7V\VWHP$=(57<
%*&'&+
7KURPELQRVFRSH3DFN
%** *+
7KURPELQRVFRSHVRIWZDUH.LWWR9
&
6\VWHPV
STA Coag Connexion System

67$&RDJ&RQQH[LRQLVWKHVSHFLDOLVHGVRIWZDUHIRUPDQDJLQJDQG
VXSHUYLVLQJ6WDJRV\VWHPV
6SHFLILFDOO\DGDSWHGWRFRDJXODWLRQ67$&RDJ&RQQH[LRQLVD
YDOXDEOHGHFLVLRQVXSSRUWWRROZLFKFDQEHFRQILJXUHGDFFRUGLQJWR
\RXUQHHGV
4

.0

$XWRPDWLFYDOLGDWLRQRIUHVXOWVDFFRUGLQJWRODERUDWRU\GHQDEOHFULWHULD
'HOWDFKHFNVFDQEHDSSOLHGWRWKHSDWLHQWVSUHYLRXVUHVXOWDQGKLVWRU\
&RDJXODWLRQVSHFLFH[SHUWUXOHV
0HDVXUHPHQWRIPXOWLGLOXWLRQIDFWRUV
'HFLVLRQWUHHIRU/XSXV$QWLFRDJXODQW/$
5HVXOWVPRQLWRULQJ
$EQRUPDOUHVXOWVDOHUWV
$XWRPDWLFUHUXQ
&RPPHQWVSUHVHWRUQRWRQUHVXOWV
+ROGVIURPWUDQVPLWWLQJUHVXOWVZKHQ4&JRHVRXWVLGHUDQJHV4&
(4

/HYH\-HQQLQJV*UDSKVDQGYDOXHWDEOHV
9LVXDODOHUWV\VWHPZLWKFRORUFRGHV
:HVWJDUG5XOHVFRQJXUHGE\4&
3RVVLELOLW\RILGHQWLI\LQJWKH4&SUHFHGLQJWKHWHVWIRUDQ\JLYHQSDUDPHWHU
&HQWUDOLVHGPRQLWRULQJRI4&ZLWKRYHUYLHZRIPXOWLSOHJUDSKV
5HPRWH4&PDQDJHPHQW
'LFWLRQDU\IRUWHVWV ([SHUWUXOHV
LIS*
4
2 /5
,QWHUIDFHEHWZHHQ/DERUDWRU\,QIRUPDWLRQ6\VWHP/,6DQGLQVWUXPHQWV
XSWRLQWHUIDFHGLQVWUXPHQWV
:RUNORDGPRQLWRULQJ
7UDQVPLVVLRQRIYDOLGDWHGSDWLHQWOHVDQGFXVWRPLVHGVXPPDU\UHSRUWVHGLWLRQ
0XOWLFULWHULDGDWDEDVHTXHULHVDJHJHQGHUSDUDPHWHUGHSDUWPHQWHWF
)LOHDUFKLYLQJOHV
(OHFWURQLFQRWHERRNWUDFNVPDLQWHQDQFHWDVNV
$FWLYLW\VWDWLVWLFVGLVSOD\HG
'LFWLRQDU\IRUWHVWV ([SHUWUXOHV

%,&&,
$=(57<
%,&&%
4:(57<
/DERUDWRU\,QIRUPDWLRQ6\VWHP/,6
6\VWHPV
&
Reagents
Reagents
&*
Screening Tests
&,
Prothrombin Time

57
$XWRPDWHGUHDJHQWV
* "
- 89:/0
8;"
3URWKURPELQ7LPH37,6,a
YLDOVRI67$1pRSODVWLQH&,
YLDOVRIVROYHQW
[PO
***
- 89:/0
8;&
YLDOVRI67$1pRSODVWLQH&,
YLDOVRIVROYHQW
[PO
* *
- 89:/0
8;0."
YLDOVRI67$1pRSODVWLQH&,3OXV
YLDOVRIVROYHQW
[PO
**,
- 89:/0
8;0.&
YLDOVRI67$1pRSODVWLQH&,3OXV
YLDOVRIVROYHQW
[PO
**"
- 89:/0
8&"
5HFRPELQDQWWKURPERSODVWLQIRU
GHWHUPLQDWLRQRI3URWKURPELQ7LPH37
,6,a
YLDOVRI67$1pRSODVWLQH5
YLDOVRIVROYHQW
[PO

- 89-<+
'HWHUPLQDWLRQRIWKHFRPELQHG
)DFWRUV,,9,,;
YLDOVRI67$63$
YLDOVRIGLOYHQW
[PO
0XOWLSXUSRVHUHDJHQWV

:/0
8;"
YLDOVRI1pRSODVWLQH&,
YLDOVRIVROYHQW
[PO
'
:/0
8;&
YLDOVRI1pRSODVWLQH&,
YLDOVRIVROYHQW
[PO
,
:/0
8;0.
YLDOVRI1pRSODVWLQH&,3OXV
YLDOVRIVROYHQW
[PO
,"
:/0
8;0."
YLDOVRIVROYHQW
[PO
,*
:/0
8;0.&
YLDOVRIVROYHQW
[PO
&
- +
'HWHUPLQDWLRQRIWKHFRPELQHG
)DFWRUV,,9,,;
YLDOVRI63$
YLDOVRIGLOXHQW
[PO
&%
6FUHHQLQJ7HVWV
)RU1RUGLFFRXQWULHVRQO\
APTT

57
"'"
- 89 .

"
'HWHUPLQDWLRQRI$FWLYDWHG3DUWLDO
7KURPERSODVWLQ7LPH$377
VLOLFDDFWLYDWRU
YLDOVRI67$377$XWRPDWH
[PO
"',
- 89
8"
NDROLQDFWLYDWRU
YLDOVRI67$&.3UHVW
YLDOVRIVROYHQWDFWLYDWRU
[PO
%
- 89 /25 8

OLTXLGUHDJHQW
YLDOVRI67$&HSKDVFUHHQ
[PO
&
- 89 /25 8&

OLTXLGUHDJHQW
YLDOVRI67$&HSKDVFUHHQ
[PO
%
.

"
VLOLFDDFWLYDWRU
YLDOVRI377$XWRPDWH
[PO
%
.

&
VLOLFDDFWLYDWRU
YLDOVRI377$XWRPDWH
[PO
"'%

8
NDROLQDFWLYDWRU
YLDOVRI&.3UHVW
[PO
%,

8"
NDROLQDFWLYDWRU
YLDOVRI&.3UHVW
[PO
"''
9=
/XSXVDQWLFRDJXODQW$377EDVHGUHDJHQW
YLDOVRI377/$
[PO
YLDOVRI3RRO1RUP
[PO
$XWRPDWHGUHDJHQWV
5HIHUHQFH3ODVPD
"'
0
1RUPDOKXPDQSODVPDSRRO
6FUHHQLQJ7HVWV
&'
Fibrinogen

57
*,

- 89=>.?
/LTXLGUHDJHQWIRUWKHTXDQWLWDWLYH
GHWHUPLQDWLRQRIEULQRJHQ
E\&ODXVVPHWKRG
YLDOVRI67$/LTXLG)LE
[PO
%
- 89?
4XDQWLWDWLYHGHWHUPLQDWLRQRIEULQRJHQ
E\&ODXVVPHWKRG
YLDOVRI67$)LE
[PO
*,
- 89? "
E\&ODXVVPHWKRG
YLDOVRI67$)LEULQRJHQ
[PO
*&
?9
8.

E\&ODXVVPHWKRG
YLDOVRI)LEUL3UHVW$XWRPDWH
[PO
%"
?9
8.

"
E\&ODXVVPHWKRG
YLDOVRI)LEUL3UHVW$XWRPDWH
[PO
$XWRPDWHGUHDJHQWV
6FUHHQLQJ7HVWV
Thrombin Time

57
$XWRPDWHGUHDJHQWV
*&&
- 89 2
'HWHUPLQDWLRQRIWKURPELQWLPH
YLDOVRI67$7KURPELQ
[PO
**'
- 89 2&
'HWHUPLQDWLRQRIWKURPELQWLPH
YLDOVRI67$7KURPELQ
[PO
*&
- 89 /
0 8
'HWHUPLQDWLRQRI5HSWLODVHWLPH
YLDOVRI67$5HSWLODVH
[PO
6FUHHQLQJ7HVWV
&

Factor Assays
Deficient Plasmas

57
,
- 89;. @;;
,PPXQRGHSOHWHGSODVPDIRUIDFWRU,,
DVVD\
YLDOVRI67$,PPXQR'HI,,
[PO
,"
- 89 A5
;;
'HFLHQWSODVPDIRUIDFWRU,,DVVD\
YLDOVRI67$'HFLHQW,,
[PO
,
- 89 A5
!
'HFLHQWSODVPDIRUIDFWRU9DVVD\
YLDOVRI67$'HFLHQW9
[PO
,
- 89 A5
!;;
,PPXQRGHSOHWHGSODVPDIRUIDFWRU9,,
DVVD\
YLDOVRI67$'HFLHQW9,,
[PO
,%
- 89 A5
B
,PPXQRGHSOHWHGSODVPDIRUIDFWRU;
DVVD\
YLDOVRI67$'HFLHQW;
[PO
([WULQVLF3DWKZD\
,QWULQVLF3DWKZD\
,%

- 89;. @!;;;
,PPXQRGHSOHWHGSODVPDIRUIDFWRU9,,,
DVVD\
YLDOVRI67$,PPXQR'HI9,,,
[PO
,

- 89;. @;B
,PPXQRGHSOHWHGSODVPDIRUIDFWRU,;
DVVD\
YLDOVRI67$,PPXQR'HI,;
[PO
,"
- 89 A5
!;;;
,PPXQRGHSOHWHGSODVPDIRUIDFWRU9,,,
DVVD\
YLDOVRI67$'HFLHQW9,,,
[PO
,
- 89 A5
;B
,PPXQRGHSOHWHGSODVPDIRUIDFWRU,;
DVVD\
YLDOVRI67$'HFLHQW,;
[PO
,
- 89 A5
B;
'HFLHQWSODVPDIRUIDFWRU;,DVVD\
YLDOVRI67$'HFLHQW;,
[PO
&"

- 89;. @B;;
,PPXQRGHSOHWHGSODVPDIRUIDFWRU;,,
DVVD\
YLDOVRI67$,PPXQR'HI;,,
[PO
)DFWRU$VVD\V
Other Techniques

57
'HFDUER[\OHG)DFWRU,,
528;!;;
4XDQWLWDWLYHGHWHUPLQDWLRQRI3,9.$,,
'HFDUER[\3URWKURPELQE\(/,6$
PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRIDQWL3,9.$,,SHUR[LGDVH
[YLDOVRI3,9.$,,FDOLEUDWRU
YLDORIZDVKLQJVROXWLRQ
WDEOHWVRI23'
WDEOHWVRIXUHDSHUR[LGH
YLDORIGLOXWLRQEXIIHU
%&
-
50
8!;;9 ?
&KURQRPHWULFGHWHUPLQDWLRQRIDFWLYDWHG
IDFWRU9,,
5HVHDUFK3URGXFW
YLDOVRIGHFLHQWSODVPD9,,
YLDOVRIUV7)3KRVSKROLSLGHV
YLDOVRIFRQWURO
YLDOVRIEXIIHU
YLDOVRI)9,,DFDOLEUDWRU
YLDOVRIFRQWURO
[PO
'&

528!;;9
4XDQWLWDWLYHGHWHUPLQDWLRQRIIDFWRU9,,D
$QWLWKURPELQFRPSOH[E\(/,6$PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRIDQWL$7SHUR[LGDVH
YLDOVRI)9,,D$7FDOLEUDWRU
YLDOVRI$7SHUR[LGDVHEXIIHU
YLDOVRIVDPSOHGLOXHQW
YLDOVRI70%
YLDOVRI)9,,D$7FRQWURO
[WHVWV
&
528!;;
4XDQWLWDWLYHGHWHUPLQDWLRQRIIDFWRU9,,$J
E\(/,6$PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRIDQWL9,,$JSHUR[LGDVH
YLDOVRI)9,,FDOLEUDWRU
YLDOVRI)9,,FRQWURO
WDEOHWVRI23'
[WHVWV
[FRDWHGVWULSV
YLDOVRIDQWL;$JSHUR[LGDVH
YLDOVRI);FDOLEUDWRU
YLDOVRI);FRQWURO
WDEOHWVRI23'
[WHVWV
%
528!;;;
4XDQWLWDWLYHGHWHUPLQDWLRQRIIDFWRU9,,,$J
E\(/,6$PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRIDQWL9,,,$JSHUR[LGDVH
YLDOVRI)9,,,$JFDOLEUDWRU
YLDOVRI)9,,,$JFRQWURO
YLDOVRI70%
YLDOVRIGLOXWLRQEXIIHU
'&'

528!)??!;;;C
4XDQWLWDWLYHGHWHUPLQDWLRQRIWKHFDSDFLW\
RI9RQ:LOOHEUDQG)DFWRUWRELQGWR)9,,,
E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI70%
YLDOVRIDQWL)9,,,SHUR[LGDVH
YLDOVRI9:))9,,,FDOLEUDWRU
YLDOVRI9:))9,,,FRQWURO
YLDOVRIUHFRPE)9,,,
YLDOVRIDQWL)9,,,SHUR[LGDVHEXIIHU
[WHVWV
[FRDWHGVWULSV
YLDOVRIDQWL,;$JSHUR[LGDVH
YLDOVRI),;$JFDOLEUDWRU
YLDOVRI),;$JFRQWURO
YLDOVRI70%
[WHVWV
YLDORISXULHGEULQRJHQ
YLDORIPRQRFKORUDFHWLFDFLG
YLDORINDROLQVXVSHQVLRQ
YLDORIFDOFLXPWKURPELQ
*&
[WHVWV
)DFWRU9,,
)DFWRU;

528B
4XDQWLWDWLYHGHWHUPLQDWLRQRIIDFWRU;$J
E\(/,6$PHWKRG
5HVHDUFK3URGXFW
)DFWRU9,,,
[WHVWV
)DFWRU,;
'
528;B
4XDQWLWDWLYHGHWHUPLQDWLRQRIIDFWRU,;$J
E\(/,6$PHWKRG
)DFWRU;,,,
%,
?5
B;;;

)DFWRU;,,,DVVD\
[PO
)DFWRU$VVD\V
"
*
Fibrin Formation & Degradation
,
Fibrin Formation

57
"
- 9=

?4
4XDQWLWDWLYHGHWHUPLQDWLRQRIEULQ
PRQRPHUVE\LPPXQRWXUELGLPHWULF
PHWKRG
YLDOVRIODWH[
YLDOVRIEXIIHU
[PO
[PO
%",
?-
'HWHFWLRQRIVROXEOHEULQPRQRPHUV
FRPSOH[HVE\KHPDJJOXWLQDWLRQ
YLDOVRI)67HVWUHDJHQW
YLDOVRISRVLWLYHFRQWURO
YLDOVRIQHJDWLYHFRQWURO
%%,
?-
D
'HWHFWLRQRIVROXEOHEULQPRQRPHUV
FRPSOH[HVE\KHPDJJOXWLQDWLRQ
YLDOVRI)67HVW8QLWUHDJHQW
YLDOVRISRVLWLYHFRQWURO
YLDOVRIQHJDWLYHFRQWURO
WHVWFDUGV
"%

5@?-

?07

WHVWFDUGV
%,
?5
B;;;

)DFWRU;,,,DVVD\
YLDORISXULHGEULQRJHQ
YLDORIPRQRFKORUDFHWLFDFLG
%
)LEULQ)RUPDWLRQ 'HJUDGDWLRQ
[PO
[PO
[
YLDORINDROLQVXVSHQVLRQ
YLDORIFDOFLXPWKURPELQ
[PO
Degradation products

57
)LEULQ'HJUDGDWLRQ3URGXFWV''LPHU
"&"
- 89=

89
4XDQWLWDWLYHGHWHUPLQDWLRQRI''LPHUE\
LPPXQRWXUELGLPHWULFPHWKRG
"
YLDORIODWH[
9
8
YLDORIQHJDWLYHFRQWURO
'HWHFWLRQRI''LPHUE\ODWH[DJJOXWLQDWLRQ YLDORISRVLWLYHFRQWURO
""

5@9
7

WHVWFDUGV
',
5289
4XDQWLWDWLYHGHWHUPLQDWLRQRI''LPHUE\
(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRIDQWL'SHUR[LGDVH
YLDOVRI''LFDOLEUDWRU
YLDOVRI''LFRQWURO
YLDOVRIODWH[
YLDOVRIEXIIHU
[PO
YLDORIEXIIHU
WHVWFDUGV
PL[LQJURGV
[PO
[
YLDOVRI70%
[WHVWV
)LEULQ )LEULQRJHQ'HJUDGDWLRQ3URGXFWV
- 89=

8?
4XDQWLWDWLYHGHWHUPLQDWLRQRIEULQDQG
EULQRJHQGHJUDGDWLRQSURGXFWVE\
LPPXQRWXUELPHWULFPHWKRG
YLDOVDIODWH[
YLDOVRIEXIIHU
"
?0
'HWHFWLRQRIEULQRJHQGHJUDGDWLRQ
SURGXFWV)'3LQSODVPDE\ODWH[
DJJOXWLQDWLRQ
YLDORIODWH[
YLDORIQHJDWLYHFRQWURO
YLDORISRVLWLYHFRQWURO
"&
?0E=
FG
YLDOVRIODWH[
[PO
""&
?0EC.@@ G
YLDOVRIEXIIHU
[PO
"%

5@?-
?0
WHVWFDUGV
7

*'
[PO
[PO
YLDORIEXIIHU
WHVWFDUGV
PL[LQJURGV
[PO
[
)LEULQ)RUPDWLRQ 'HJUDGDWLRQ
'
Fibrinolysis
&
Fibrinolysis

57
*
- 9-
52 ?;
&KURPRJHQLFDVVD\IRUWKHTXDQWLWDWLYH
GHWHUPLQDWLRQRIWKHWKURPELQDFWLYDWDEOH
EULQRO\VLVLQKLELWRU7$),DFWLYLW\
5HVHDUFK3URGXFW
YLDOVRI7$),DFWLYDWRU
YLDOVRIFDUER[\SHSWLGDVH$
YLDOVRIVXEVWUDWH
*&*
528 ?;3 ?;

4XDQWLWDWLYHGHWHUPLQDWLRQRIDFWLYDWHG
DQGRULQDFWLYDWHG7$),E\(/,6$PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRI70%
YLDOVRIDQWL7$),D7$),DLSHUR[LGDVH YLDOVRIGLOXWLRQEXIIHU
YLDOVRI7$),D7$),DLFDOLEUDWRU
YLDOVRI7$),D7$),DLFRQWURO
[WHVWV
*"%
- 89-
5280
&KURPRJHQLFDVVD\RISODVPLQRJHQ
YLDOVRIVWUHSWRNLQDVH
YLDOVRIVXEVWUDWH
[PO
*"'
- 89-
528
/0
&KURPRJHQLFDVVD\RIDQWLSODVPLQ
YLDOVRISODVPLQ
YLDOVRIVXEVWUDWH
YLDOVRIVROYHQW
'%
528

4XDQWLWDWLYHGHWHUPLQDWLRQRIWLVVXH
3ODVPLQRJHQ$FWLYDWRUW3$E\(/,6$
PHWKRG
[FRDWHGVWULSV
YLDOVRIDQWLW3$SHUR[LGDVH
YLDOVRIW3$FDOLEUDWRU
YLDOVRIW3$FRQWURO
YLDOVRI70%
% ,
-
528;
&KURPRJHQLFDVVD\RI3ODVPLQRJHQ
$FWLYDWRU,QKLELWRU3$,
YLDOVRIXURNLQDVH
YLDOVRISODVPLQRJHQ
YLDOVRIVXEVWUDWH
YLDOVRI3$,FDOLEUDWRU
''
528;9&
4XDQWLWDWLYHGHWHUPLQDWLRQRI3ODVPLQRJHQ
$FWLYDWRU,QKLELWRU3$,E\(/,6$
PHWKRG
[FRDWHGVWULSV
YLDOVRIDQWL3$,SHUR[LGDVH
YLDOVRI3$,FRQWURO
YLDOVRI70%
)LEULQRO\VLV
YLDOVRI7$),FDOLEUDWRU
YLDOVRI7$),FRQWURO
WHVWV
[PO
[WHVWV
[PO
[WHVWV
Anticoagulant Treatments
Heparins & Direct Anti-Xa

57
&&
- 89=>.
9B
/LTXLGUHDJHQWIRUWKHFKURPRJHQLFDVVD\
RI8)+/0:+IRQGDSDULQX[$UL[WUD
DQGULYDUR[DEDQ;DUHOWR
YLDOVRIVXEVWUDWH
YLDOVRIIDFWRU;D
[PO

- 89=>.
9B%
/LTXLGUHDJHQWIRUWKHFKURPRJHQLFDVVD\
RI8)+/0:+IRQGDSDULQX[$UL[WUD
DQGULYDUR[DEDQ;DUHOWR
YLDOVRIVXEVWUDWH
YLDOVRIIDFWRU;D
[PO
' *
-
528# /
&KURPRJHQLFDVVD\RI8)+DQG/0:+
YLDOVRIDQWLWKURPELQ
YLDORIEXIIHU
YLDOVRIIDFWRU;D
YLDOVRIVXEVWUDWH
YLDOVRIVXEVWUDWHSODVPD
YLDOVRIIDFWRU;D
YLDOVRISKRVSKROLSLGV&D
$QWL;DFKURPRJHQLFDVVD\V
[PO
$QWL;DFORWWLQJDVVD\
*'&
- 89-
50
8# /&
&ORWWLQJDVVD\RI8)+DQG/0:+
[PO
+HSDULQ,QGXFHG7KURPERF\WRSHQLD
& "%

- 5F/
8#; "
/DWHUDO)ORZ,PPXQRDVVD\WRGHWHFW,J*
DQWLERGLHVDJDLQVW3)
WHVWV
YLDORIEXIIHU
[WHVWV
& "'

- 5F/
8#;
/DWHUDO)ORZ,PPXQRDVVD\WRGHWHFW,J*
DQWLERGLHVDJDLQVW3)
WHVWV
YLDORIEXIIHU
[WHVWV
*&"
528#;
'HWHUPLQDWLRQRIDQWLKHSDULQ3)
DQWLERGLHVE\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI+3,$UHIHUHQFH
YLDOVRIDQWLKXPDQ,J*$
0SHUR[LGDVH
YLDOVRI+3,$QHJDWLYHFRQWURO
YLDOVRI+3,$SRVLWLYHFRQWURO
YLDOVRI70%
[[WHVWV
*

528#;9;H
'HWHUPLQDWLRQRIDQWLKHSDULQ3)
DQWLERGLHVRI,J*FODVVE\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI+3,$UHIHUHQFH
YLDOVRIDQWLKXPDQ,J*
SHUR[LGDVH
YLDOVRI+3,$QHJDWLYHFRQWURO
YLDOVRI+3,$SRVLWLYHFRQWURO
YLDOVRI70%
[[WHVWV
)LEULQRO\VLV
Heparins & Direct Anti-Xa

90
/09
0

- 89=>.
9B
&&E0G3
E%0G
40 5.0
D?#J=4)#
?/.F
KF
&DOLEUDWLRQW\SH
'HGLFDWHGFDOLEUDWLRQ8)+/0:+
+\EULGFDOLEUDWLRQ
'HGLFDWHGFDOLEUDWLRQ
&DOLEUDWLRQ
'HGLFDWHG
&DOLEUDWLRQSODVPD
- 894.0
9# /0

&DW1U
- 89?/.F
0

&DW1U
- 89KF
0

&DW1U
4XDOLW\&RQWUROV
- 89(.0
#?3D?#3- 89(.0
#C43=4)#
&DW1U&DW1U
- 89?/.F

0
&DW1U
- 89KF

0
&DW1U

90
/09
0

- 89-
50
8# /
*'&
-
528# /
' *
40 5.0
D?#
=4)#
&DOLEUDWLRQW\SH
'HGLFDWHGFDOLEUDWLRQ8)+
'HGLFDWHGFDOLEUDWLRQ/0:+
&DOLEUDWLRQSODVPD
- 89# /8#
&DW1U
- 89# /8#C4
&DW1U
4XDOLW\&RQWUROV
- 89# /
0ED?#G
&DW1U
- 89#C43=4)#
0
&DW1U
"
Direct Thrombin Inhibitors

& "&

9#
&KURPRJHQLFDVVD\RIGLUHFWWKURPELQ
LQKLELWRUVKLUXGLQ DQDORJXHVOHSLUXGLQ
GHVLUXGLQ
YLDOVRIEXIIHU
YLDORIVXEVWUDWH
YLDOVRIHFDULQ
(&$+VWDQGDUGJPO
(&$+VWDQGDUGJPO
(&$+FRQWUROJPO
[WHVWV
& "

9
&KURPRJHQLFDVVD\RIV\QWKHWLFGLUHFW
WKURPELQLQKLELWRUVGDELJDWUDQELYDOLUXGLQ
DUJDWUREDQ
YLDOVRIEXIIHU
YLDORIVXEVWUDWH
YLDOVRIHFDULQ
(&$7VWDQGDUGJPO
(&$7VWDQGDUGJPO
(&$7FRQWUROJPO
[WHVWV
& "

9#5
0
(&$+FRQWUROJPO
[PO
& "

9

(&$7VWDQGDUGJPO
(&$7VWDQGDUGJPO
[[PO
& ""

9 5
0

(&$7FRQWURODUJDWUREDQORZJPO
(&$7FRQWURODUJDWUREDQKLJKJPO
[[PO
& "*

9
K0.
(&$7VWDQGDUGJPO
(&$7VWDQGDUGJPO
[[PO
& ",

9 5
0K0.
(&$7FRQWUROJPO
[PO
*
$QWLFRDJXODQW7UHDWPHQWV
57
Thrombophilia
,
Antithrombin & Protein C

57
$QWLWKURPELQ$7
"'*
- 89-
528 ;;;
&KURPRJHQLFDVVD\RI$QWLWKURPELQ
YLDOVRIWKURPELQ
YLDOVRIVXEVWUDWH
YLDOVRIWKURPELQVROYHQW
*,
- 89-
528 ;;;*
&KURPRJHQLFDVVD\RI$QWLWKURPELQ
YLDOVRIWKURPELQ
YLDOVRIVXEVWUDWH
YLDOVRIWKURPELQVROYHQW
"*%
=

8 ;;;
YLDOVRIODWH[
4XDQWLWDWLYHGHWHUPLQDWLRQRI$QWLWKURPELQ YLDOVRIEXIIHU
E\LPPXQRWXUELGLPHWULFPHWKRG
[PO
[PO
[PO
3URWHLQ&
,,
- 89-
50
8

&ORWWLQJDVVD\RI3URWHLQ&
YLDOVRI3&GHFLHQWSODVPD
YLDOVRI3&DFWLYDWRU
[PO
*,&
- 89-
528

&KURPRJHQLFDVVD\RI3URWHLQ&
YLDOVRI3&DFWLYDWRU
YLDOVRIVXEVWUDWH
[PO
'
528

4XDQWLWDWLYHGHWHUPLQDWLRQRI3URWHLQ&E\
(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI3URWHLQ&FRQWURO
YLDOVRI70%
YLDOVRIDQWL3URWHLQ&SHUR[LGDVH YLDOVRIGLOXWLRQEXIIHU
YLDOVRI3URWHLQ&FDOLEUDWRU
[WHVWV
$FWLYDWHG3URWHLQ&5HVLVWDQFH$3&5
,&
%
- 89-
50
89
&ORWWLQJWHVWIRUWKHGHWHFWLRQRI$3&
5HVLVWDQFH
7KURPERSKLOLD
YLDOVRI)9GHFLHQWSODVPD
YLDOVRI$3&
YLDOVRIYHQRP
YLDOVRI&RQWURO1
YLDOVRI&RQWURO3
[PO
Protein S & C4b-Binding Protein

57
3URWHLQ6
,*
- 89-
50
8
&ORWWLQJDVVD\RI3URWHLQ6
",
- 89=

8?
-
YLDOVRIODWH[
4XDQWLWDWLYHGHWHUPLQDWLRQRI)UHH
YLDOVRIEXIIHU
3URWHLQ6E\LPPXQRWXUELGLPHWULFPHWKRG
[PO
"&*
- 89=

8?
-*
YLDOVRIODWH[
4XDQWLWDWLYHGHWHUPLQDWLRQRI)UHH
YLDOVRIEXIIHU
3URWHLQ6E\LPPXQRWXUELGLPHWULFPHWKRG
[PO
'"
528
0
4XDQWLWDWLYHGHWHUPLQDWLRQRI7RWDO
3URWHLQ6
E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI7RWDO3URWHLQ6FDOLEUDWRU
YLDOVRI70%
[WHVWV
YLDOVRI7RWDO3URWHLQ6FRQWURO
YLDOVRIDQWL7RWDO3URWHLQ6SHUR[LGDVH
'*
528?
4XDQWLWDWLYHGHWHUPLQDWLRQRI)UHH3URWHLQ
6E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI)UHH3URWHLQ6FDOLEUDWRU
YLDOVRI70%
[WHVWV
YLDOVRI)UHH3URWHLQ6FRQWURO
YLDOVRIDQWL)UHH3URWHLQ6SHUR[LGDVH
YLDOVRI36GHFLHQWSODVPD
YLDOVRIIDFWRU9D
YLDOVRI$3&
[PO
&E%LQGLQJ3URWHLQ
"%&
=

89C
4XDQWLWDWLYHGHWHUPLQDWLRQRI&E%3
E\LPPXQRWXUELGLPHWULFPHWKRG
5HVHDUFK3URGXFW
YLDOVRIODWH[
YLDOVRIEXIIHU
[PO
7KURPERSKLOLD
'
Others Inhibitors

57
+HSDULQ&RIDFWRU,,+&,,
%"&
-
528#;;
YLDOVRIWKURPELQ
&KURPRJHQLFDVVD\RIKHSDULQFRIDFWRU,, YLDOVRIVXEVWUDWH
5HVHDUFK3URGXFW
YLDOVRIEXIIHU
[PO
7LVVXH)DFWRU3DWKZD\,QKLELWRU7)3,
*&
528
0 ?;
4XDQWLWDWLYHGHWHUPLQDWLRQRI7RWDO7LVVXH
)DFWRU3DWKZD\,QKLELWRU7)3,E\(/,6$
PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRI7RWDO7)3,FDOLEUDWRU
YLDOVRI7RWDO7)3,FRQWURO
YLDOVRIDQWL7RWDO7)3,SHUR[LGDVH
WDEOHWVRI23'
[WHVWV
*
528? ?;
4XDQWLWDWLYHGHWHUPLQDWLRQRI)UHH7LVVXH
)DFWRU3DWKZD\,QKLELWRU7)3,E\(/,6$
PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRI)UHH7)3,FDOLEUDWRU
YLDOVRI)UHH7)3,FRQWURO
YLDOVRIDQWL)UHH7)3,SHUR[LGDVH
WDEOHWVRI23'
[WHVWV
6ROXEOH(QGRWKHOLDO3URWHLQ&5HFHSWRUV(3&5
*
528
4XDQWLWDWLYHGHWHUPLQDWLRQRIVROXEOH
(QGRWKHOLDO3URWHLQ&5HFHSWRUE\(/,6$
PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDORIZDVK6ROXWLRQ
YLDOVRIV(3&5FDOLEUDWRU
YLDOVRIDQWLV(3&5SHUR[LGDVH
YLDOVRI70%
YLDOVRIV(3&5FRQWURO
[FRDWHGVWULSV
WDEOHWVRIXUHDSHUR[\GH
YLDOVRI3URWHLQ=FDOLEUDWRU
YLDOVRIDQWLSURWHLQ=SHUR[LGDVH
WDEOHWVRI23'
[WHVWV
3URWHLQ=
&%
528

4XDQWLWDWLYHGHWHUPLQDWLRQRI3URWHLQ=
E\(/,6$PHWKRG
5HVHDUFK3URGXFW
7KURPERSKLOLD
[WHVWV
Lupus Anticoagulant (LA)

57
'
- 89-
50
8!!-5
'HWHFWLRQRIWKH/XSXV$QWLFRDJXODQWVE\
WKHGLOXWHG5XVVHOVYLSHUYHQRPWHVW
YLDOVRI67$6WDFORW'5996FUHHQ
[PO

- 89-
50
8!!-5 "
'HWHFWLRQRIWKH/XSXV$QWLFRDJXODQWVE\
YLDOVRI67$6WDFORW'5996FUHHQ
[PO

- 89-
50
8!!A
&RQUPDWLRQRI/XSXV$QWLFRDJXODQWVE\
YLDOVRI67$6WDFORW'599&RQUP
[PO
"''
9=
/XSXV$QWLFRDJXODQW$377EDVHGUHDJHQW
YLDOVRI377/$
[PO
-
50
8=
YLDOVRIKH[DJRQDOSKRVSKROLSLGV
YLDOVRIQRUPDOSODVPD
+H[DJRQDOSKRVSKROLSLGVVFUHHQLQJDQG
FRQUPDWRU\DVVD\IRU/XSXV$QWLFRDJXODQW YLDOVRI377/6
/XSXV$QWLFRDJXODQWV/$
YLDOVRIEXIIHU
YLDOVRIVROYHQW
[WHVWV
5HIHUHQFH3ODVPD
"'
0
1RUPDOKXPDQSODVPDSRRO
YLDOVRI3RRO1RUP
[PO
7KURPERSKLOLD
&
Antiphospholipid Antibodies (APA)

**
52 -5
4XDOLWDWLYHGHWHUPLQDWLRQRI,J*,J$,J0
DQWLSKRVSKROLSLGDQWLERGLHV
E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI$QWL,J*$0SHUR[LGDVH
YLDOVRI$3$6FUHHQUHIHUHQFH
YLDOVRI70%
YLDOVRIFRQWURO
YLDOVRIFRQWURO
*,
528;HM4
4XDQWLWDWLYHGHWHUPLQDWLRQRIDQWL
SKRVSKROLSLGDQWLERGLHV,J*DQGRU,J0
E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI$QWL,J*SHUR[LGDVH
YLDOVRI$QWL,J0SHUR[LGDVH
YLDOVRI$3$,J*0FDOLEUDWRU
YLDOVRI70%
YLDOVRIFRQWURO
YLDOVRIFRQWURO
*%
528
9NH;;H
4XDQWLWDWLYHGHWHUPLQDWLRQRIDQWL*3,
DQWLERGLHV,J*E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI$QWL*3,,J*FDOLEUDWRU
YLDOVRI70%
YLDOVRIFRQWURO
YLDOVRIFRQWURO
[WHVWV
*'
528
9NH;;4
4XDQWLWDWLYHGHWHUPLQDWLRQRIDQWL*3,
DQWLERGLHV,J0E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRI$QWL*3,,J0FDOLEUDWRU
YLDOVRI70%
YLDOVRIFRQWURO
YLDOVRIFRQWURO
[WHVWV
*"
528
9
2;HM4
4XDQWLWDWLYHGHWHUPLQDWLRQRIDQWL
SURWKURPELQDQWLERGLHV,J*DQGRU,J0
E\(/,6$PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRI$QWL3URWKURPELQ,J*0FDOLEUDWRU
YLDOVRI70%
YLDOVRIFRQWURO
YLDOVRIFRQWURO
7KURPERSKLOLD
57
[WHVWV
[WHVWV
[WHVWV
Primary Haemostasis
Von Willebrand Factor & Activation Markers

57
9RQ:LOOHEUDQG)DFWRU
"&%
- 89=

8!)?
4XDQWLWDWLYHGHWHUPLQDWLRQRI9RQ
YLDOVRIODWH[
:LOOHEUDQG)DFWRUE\LPPXQRWXUELGLPHWULF YLDOVRIEXIIHU
PHWKRG
'
528!)?
4XDQWLWDWLYHGHWHUPLQDWLRQRI9RQ
:LOOHEUDQG)DFWRUE\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRIDQWL9:)SHUR[LGDVH
YLDOVRI9:)FDOLEUDWRU
YLDOVRI9:)FRQWURO
YLDOVRI70%
'
528!)?C
RI9RQ:LOOHEUDQG)DFWRUWRELQGWR
&ROODJHQE\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRIDQWL9:)SHUR[LGDVH
YLDOVRI9:)&%FDOLEUDWRU
YLDOVRI9:)&%FRQWURO
YLDOVRI70%
'&'
528!)??!;;;C
RI9RQ:LOOHEUDQG)DFWRUWRELQGWR)9,,,
E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRIDQWL)9,,,SHUR[LGDVH
YLDOVRI9:))9,,,FDOLEUDWRU
YLDOVRI9:))9,,,FRQWURO
YLDOVRIDQWL)9,,,SHUR[LGDVHEXIIHU
YLDOVRI70%
YLDOVRIUHFRPE)9,,,
" &

5
+
5HVHDUFK3URGXFW
YLDORI5LVWRFHWLQ
YLDOVRIODWH[GLOXHQW
[PO
[WHVWV
[WHVWV
[WHVWV
PJ
$FWLYDWLRQ0DUNHUV
'"
528N9 H
4XDQWLWDWLYHGHWHUPLQDWLRQRI
7KURPERJOREXOLQ7*
[FRDWHGVWULSV
YLDOVRIDQWL7*SHUR[LGDVH
YLDOVRI7*FDOLEUDWRU
YLDOVRI7*FRQWURO
YLDOVRI70%
'"&
528?
4XDQWLWDWLYHGHWHUPLQDWLRQRI3ODWHOHW
)DFWRU3)E\(/,6$PHWKRG
[FRDWHGVWULSV
YLDOVRIDQWL3)SHUR[LGDVH
YLDOVRI3)FDOLEUDWRU
YLDOVRI3)FRQWURO
YLDOVRI70%
,*
528H!
4XDQWLWDWLYHGHWHUPLQDWLRQRIVROXEOH*39
E\(/,6$PHWKRG
5HVHDUFK3URGXFW
[FRDWHGVWULSV
YLDOVRI*39FDOLEUDWRU
YLDOVRIDQWLVROXEOH*39SHUR[LGDVH
YLDOVRI70%
YLDOVRI*39FRQWURO
3ULPDU\+DHPRVWDVLV
[WHVWV
[WHVWV
[WHVWV
Platelets*

57
)ORZ&\WRPHWU\$VVD\V
'
= !-3&
)RUWKHPRQLWRULQJRI3<$'3UHFHSWRU
DQWDJRQLVWVE\RZF\WRPHWU\
YLDORIGLOXHQW
YLDORIVWDLQLQJUHDJHQW
YLDORI3*($'3
YLDORIDQWL9$633PRXVHPRQRFORQDODQWLERG\ YLDORI3*(
YLDORIQHJDWLYHLVRW\SLFFRQWURO
YLDORI[DWLYHDJHQW
VDPSOHV
&&&
= H 5 /

4XDQWLWDWLYHGHWHUPLQDWLRQRISODWHOHW
VXUIDFHJO\FRSURWHLQVE\RZF\WRPHWU\
YLDORIGLOXHQW
YLDORIDQWL*S,,E,,,D
YLDORIDQWL*S,,,D
YLDORI[DWLYHDJHQW
YLDORI75$3
YLDORIDQWL*S,E
YLDORIDQWL*03
YLDORIFDOLEUDWRU
VDPSOHV
&'
= #9&
'HWHUPLQDWLRQRIWKH3ODWHOHW+3$
SRO\PRUSKLVPE\RZF\WRPHWU\
YLDORIGLOXHQW
YLDORIFDOLEUDWRU
YLDORI0$EDQWL*S,,,D
YLDORI0$EDQWL*S,,,D
"
0
0
;
.LWIRU3ODWHOHW$VVRFLDWHG,PPXQRJOREXOLQ
TXDQWLWDWLRQE\RZF\WRPHWU\
5HVHDUFK3URGXFW
YLDORIGLOXHQW
YLDORI0DE
YLDORIFDOLEUDWRU
YLDORIEXIIHU
VDPSOHV
&&
0
0
H/;;3;;;O55./5
0RQLWRULQJRIWKH*S,,E,,,D2FFXSDQF\E\
RZF\WRPHWU\
5HVHDUFK3URGXFW
YLDORIGLOXHQW
YLDORI0DEDQWL*S,,,D
YLDORI0DEDQWL*S,,,D
YLDORIFDOLEUDWRU
VDPSOHV
",
0
0
0

.LWIRUFXVWRPLVHGSODWHOHWDQWLJHQ
TXDQWLWDWLRQE\RZF\WRPHWU\
5HVHDUFK3URGXFW
YLDORIQHJDWLYHLVRW\SLFFRQWURO,J*
YLDORIQHJDWLYHLVRW\SLFFRQWURO,J*D
YLDORIQHJDWLYHLVRW\SLFFRQWURO,J*E
YLDORIGLOXHQW
YLDORIFDOLEUDWRU
WHVWV
&%
0
0
H-5
.LWIRUSODWHOHWJO\FRSURWHLQTXDQWLWDWLRQE\
RZF\WRPHWU\
5HVHDUFK3URGXFW
YLDORIGLOXHQW
YLDORIFDOLEUDWRU
YLDORI0DEDQWL*S,D
YLDORI0DEDQWL*S,E
YLDORI0DEDQWL*S,,,D
VDPSOHV

4 F
%HDGVIRUF\WRPHWHUVHWWLQJVLQ
PLFURSDUWLFOHDQDO\VLV
5HVHDUFK3URGXFW
YLDORIEHDOV
00>.
#
.LWIRU3DUR[\VPDO1RFWXUQDO
+DHPRJORELQXULDGLDJQRVLVRQ
JUDQXORF\WHVE\RZF\WRPHWU\
YLDORIGLOXHQW
YLDORIFDOLEUDWHGEHDGV
YLDORIVDWXUDWLRQUHDJHQW
YLDOVRIUHGFHOOO\VLQJVROXWLRQ
YLDORI0DEDQWL&'
YLDORI0DEDQWL&'

>.
#
.LWIRU3DUR[\VPDO1RFWXUQDO
+DHPRJORELQXULDGLDJQRVLVRQUHGEORRG
FHOOVE\RZF\WRPHWU\
YLDORIGLOXHQW
YLDOVRIFDOLEUDWHGEHDGV
YLDORIVDWXUDWLRQUHDJHQW
YLDORI0DEDQWL&'
YLDORI0DEDQWL&'
&
00>.
0

.LWIRUFXVWRPLVHGOHXNRF\WHVXUIDFH
DQWLJHQTXDQWLWDWLRQE\RZF\WRPHWU\
5HVHDUFK3URGXFW
YLDORIGLOXHQW
VROXWLRQ
YLDORIFDOLEUDWLRQEHDGV
YLDORIQHXWUDOLVDWLRQ
&
&
&
VDPSOHV
WHVWV
VDPSOHV
VDPSOHV
WHVWV
3ULPDU\+DHPRVWDVLV
"
Monoclonal Antibodies For Flow Cytometry*

57
$QWLSODWHOHWPDUNHUV
&
M50 CM/.@
$YDLODELOLW\PRQWKVPD[LPXP
PJ
& &
*M50 & "M/.@
PJ
&
*M50 & "M?;
WHVWV
&
*M50 & "M
WHVWV
& "
&M50 =9'M/.@
PJ
&
&M50 =9'M?;
WHVWV
& *
&M50 =9'M
WHVWV
& %
M50 =4&'M/.@
PJ
& ,
M50 =4&'M?;
WHVWV
& '
M50 =4&'M
WHVWV
& &
*&M50 =&%M/.@
PJ
&
*&M50 =&%M?;
WHVWV
&
*&M50 =&%M
WHVWV
& &,
*&M50 ?%M/.@
PJ
& &*
*&M50 ?%M?;
WHVWV
&
*M50 = M/.@
PJ
& &
*M50 = M?;
WHVWV
&
*M50 = M
WHVWV
&
? M50 '?'M?;
WHVWV
"
$QWLHQGRWKHOLDOFHOOPDUNHUV
&
*
&*M50 O4'M/.@
WHVWV
&
,
&*M50 O4?*M/.@
WHVWV
&
%
&*M50 O4"H*M/.@
WHVWV
& &&
&*M50 O4,M/.@
WHVWV
& &
&*M50 O4,M?;
WHVWV
&
&*M50 O4,MC

WHVWV
& &
&*M50 -9O&M/.@
WHVWV
& &
&*M50 -9O&M?;
WHVWV
& &"
&*M50 -9O&M
WHVWV
& &
&*M50 -9O&MC

WHVWV
'
*
3ULPDU\+DHPRVWDVLV

57
,VRW\SLF1HJDWLYH&RQWUROV
& &'

0 ;H&/.@E#&&G
PJ
& &%

0 ;H&9?; E#&&G
WHVWV
&

0 ;H&9E#&&G
WHVWV
& %

0 ;H/.@E&*&G
PJ
& ,

0 ;H9?; E&*&G
WHVWV
& '

0 ;H9E&*&G
WHVWV
& "

0 ;H/.@E&H"G
PJ
&

0 ;H9?; E&H"G
WHVWV
& *

0 ;H9E&H"G
WHVWV
3ULPDU\+DHPRVWDVLV
,
%
Calibrators & Controls
'
Calibration Plasmas

57
$XWRPDWHG5HDJHQWV
*,"
- 89D50

&DOLEUDWLRQSODVPDIRU37EULQRJHQ
IDFWRUDVVD\V,,99,,9,,,,;;;,;,, YLDOVRI67$8QLFDOLEUDWRU
$73&36SODVPLQRJHQDQWLSODVPLQ
DFWLYLW\
[PO
"
- 89!)?0

&DOLEUDWLRQSODVPDIRUDVVD\RI9RQ
:LOOHEUDQGIDFWRUE\LPPXQRWXUELGLPHWULF
PHWKRG
YLDOVRI67$9:)$J&DOLEUDWRU
[PO
"
- 89?40

&DOLEUDWLRQSODVPDVIRUDVVD\RIEULQ
PHWKRG67$/LDWHVW)0
YLDOVRI67$)0&DOLEUDWRU
[[PO
- 89?0

&DOLEUDWLRQSODVPDVIRUDVVD\RIEULQ
DQGEULQRJHQGHJUDGDWLRQSURGXFWVE\
67$/LDWHVW)'3
YLDOVRI67$)'3&DOLEUDWRU
[[PO
*%
- 89# /8#
&DOLEUDWLRQSODVPDVIRU8)+DVVD\XVLQJ
DQWL;DPHWKRG67$6WDFORW+HSDULQ
6WDFKURP+HSDULQ
YLDOVRI67$+HSDQRUP+
YLDOVRI67$+HSDQRUP+
YLDOVRI67$+HSDQRUP+
[[PO
*%&
- 89# /8#C43=4)#
&DOLEUDWLRQSODVPDVIRU/0:+DVVD\
XVLQJDQWL;DPHWKRG67$6WDFORW
+HSDULQ6WDFKURP+HSDULQ
YLDOVRI67$+HSDQRUP+%30/0:+
[[PO
- 894.0
# /0

&DOLEUDWLRQSODVPDVIRU+HSDULQVDVVD\
8)+DQG/0:+XVLQJDQWL;DPHWKRG
67$/LTXLG$QWL;D
YLDOVRI67$0XOWL+HS&DOLEUDWRU
[[PO
"
- 89?/.F0

&DOLEUDWLRQSODVPDVIRUIRQGDSDULQX[
$UL[WUDDVVD\XVLQJDQWL;DPHWKRG
67$/LTXLG$QWL;D
YLDOVRI67$)RQGDSDULQX[&DOLEUDWRU
[[PO
,
- 89KF0

&DOLEUDWLRQSODVPDVIRUULYDUR[DEDQ
;DUHOWRDVVD\XVLQJDQWL;DPHWKRG
67$/LTXLG$QWL;D
YLDOVRI67$5LYDUR[DEDQ&DOLEUDWRU
[[PO
*""
%
(&$OLQH
& "

9

(&$7VWDQGDUGJPO
(&$7VWDQGDUGJPO
[[PO
& "*

9
K0.
(&$7VWDQGDUGJPO
(&$7VWDQGDUGJPO
[[PO
*"
D50

&DOLEUDWLRQSODVPDIRU37EULQRJHQ
YLDOVRI8QLFDOLEUDWRU
IDFWRUDVVD\V,,99,,9,,,,;;;,;,,
$7DQWLJHQ3&36DFWLYLW\
[PO
'*

0>.578
&DOLEUDWLRQSODVPDVIRUWKHGHWHUPLQDWLRQ
RI3URWKURPELQ7LPH,15
[[PO
"
&DOLEUDWRUV &RQWUROV
YLDOVRI(WDORTXLFN
YLDOVRI(WDORTXLFN
YLDOVRI(WDORTXLFN
Control Plasmas

57
""

- 89.
(0+
1RUPDODQGDEQRUPDOFRQWUROSODVPDVIRU
37,15$377EULQRJHQWKURPELQWLPH
1DQG$7DFWLYLW\VWDEOHK
YLDOVRI67$5RXWLQH4&PO1
YLDOVRI67$5RXWLQH4&PO3
[[PO
,&

- 89.
(0.+
$EQRUPDOFRQWUROSODVPDVIRU37$377
EULQRJHQWKURPELQWLPHDQG$7DFWLYLW\
VWDEOHK
YLDOVRI67$5RXWLQH4&33OXV
[PO
*,'
- 89
0<
37$377EULQRJHQWKURPELQWLPH1
DQG$7DFWLYLW\
YLDOVRI67$&RDJ&RQWURO1
YLDOVRI67$&RDJ&RQWURO3
[[PO
*,%
- 89-

0<
1RUPDODQGDEQRUPDOFRQWUROSODVPDV
IRU37$377EULQRJHQWKURPELQWLPH
1UHSWLODVHWLPH1IDFWRUDVVD\V,,
99,,9,,,,;;;,;,,$73&36
SODVPLQRJHQDQWLSODVPLQDFWLYLW\
YLDOVRI67$6\VWHP&RQWURO1
YLDOVRI67$6\VWHP&RQWURO3
[[PO
& *
- 89-5++
1RUPDOFRQWUROSODVPDIRU37$377
EULQRJHQDQG$7
YLDOVRI67$6FDQGLQRUP
[PO
& ,
- 89-5/
2++
$EQRUPDOFRQWUROSODVPDIRU37$377
DQGEULQRJHQ
YLDOVRI67$6FDQGLSDWK
[PO
"*
- 89=

8
0<
1RUPDODQGDEQRUPDOFRQWUROSODVPDV
IRUDVVD\VRI9RQ:LOOHEUDQG)DFWRU
IUHH3URWHLQ6DQG''LPHUE\LPPXQR
WXUELGLPHWULFPHWKRG
YLDOVRI67$/LDWHVW&RQWURO1
YLDOVRI67$/LDWHVW&RQWURO3
[[PO
&
- 89
0=&<
&RQWUROSODVPDVIRUOXSXVDQWLFRDJXODQW
WHVWV
YLDOVRI67$&RQWURO/$
YLDOVRI67$&RQWURO/$
[[PO
""
- 89?4
0
&RQWUROSODVPDVIRUDVVD\RIEULQ
PHWKRG67$/LDWHVW)0
YLDOVRI67$)0&RQWURO
YLDOVRI67$)0&RQWURO
[[PO
*"

- 89?
0
&RQWUROSODVPDVIRUDVVD\RIEULQDQG
EULQRJHQGHJUDGDWLRQSURGXFWVE\
67$/LDWHVW)'3
YLDOVRI67$)'3&RQWURO
YLDOVRI67$)'3&RQWURO
[[PO
*%
- 89#C43=4)#
0
&RQWUROSODVPDVIRU/0:+DVVD\XVLQJ
6WDFKURP+HSDULQ
YLDOVRI67$4XDOLW\+%30/0:+&RQWURO
YLDOVRI67$4XDOLW\+%30/0:+&RQWURO
[[PO
*%
- 89# /
0
&RQWUROSODVPDVIRU8)+DVVD\XVLQJ
6WDFKURP+HSDULQ
YLDOVRI67$+HSDULQ&RQWURO
YLDOVRI67$+HSDULQ&RQWURO
[[PO
%&

- 89(.0
#?3D?#
&RQWUROSODVPDVIRU8)+DVVD\XVLQJDQWL
;DPHWKRG67$/LTXLGDQWL;D
YLDOVRI67$4XDOLW\+1)8)+
YLDOVRI67$4XDOLW\+1)8)+
[[PO
$XWRPDWHG5HDJHQWV
)RU1RUGLFFRXQWULHVRQO\
"&
Control Plasmas

57
*%*
- 9(.0
#C43=4)#
&RQWUROSODVPDVIRU/0:+DVVD\XVLQJ
DQWL;DPHWKRG67$/LTXLGDQWL;D
YLDOVRI67$4XDOLW\+%30/0:+
YLDOVRI67$4XDOLW\+%30/0:+
[[PO
""
- 89?/.F
0
&RQWUROSODVPDVIRUIRQGDSDULQX[$UL[WUD YLDOVRI67$)RQGDSDULQX[&RQWURO
DVVD\XVLQJDQWL;DPHWKRG67$/LTXLG YLDOVRI67$)RQGDSDULQX[&RQWURO
$QWL;D
[[PO
, *

- 89KF
0
&RQWUROSODVPDVIRUULYDUR[DEDQ;DUHOWR
DVVD\XVLQJDQWL;DPHWKRG67$/LTXLG
$QWL;D
YLDOVRI67$5LYDUR[DEDQ&RQWURO
YLDOVRI67$5LYDUR[DEDQ&RQWURO
[[PO
9#5
0
(&$+FRQWUROJPO
[PO
9 5
0

(&$7FRQWURODUJDWUREDQORZJPO
(&$7FRQWURODUJDWUREDQKLJKJPO
[[PO
9 5
0K0.
(&$7FRQWUROJPO
[PO
(&$OLQH
& "
& ""
& ",
*&

0<
YLDOVRI&RDJ&RQWURO1
YLDOVRI&RDJ&RQWURO3
[[PO
*&,
-

0<
5HSWLODVHWLPH1IDFWRUDVVD\V,,99,,
9,,,,;;;,;,,$7DQWLJHQ3&36
DFWLYLW\
YLDOVRI6\VWHP&RQWURO1
YLDOVRI6\VWHP&RQWURO3
[[PO
"
98
8QDVVD\HGQRUPDOFRQWUROSODVPDIRU37
$377DQGEULQRJHQ
YLDOVRI&RDJ1RUP
[PO
"
9
28
8QDVVD\HGDEQRUPDOFRQWUROSODVPDIRU
37$377DQGEULQRJHQ
YLDOVRI&RDJ3DWK
[PO
4XDOLW\&RQWURO3URJUDPV
"
(.0-

([WHUQDOTXDOLW\FRQWUROSURJUDPRSHQWR
HYHU\FRDJXODWLRQDQDO\VHUV
4XDOLULV4&3UHPLXP
4XDOLULV4&([SHULHQFH
4XDOLULV4&+HSDULQ+1)8)+
4XDOLULV4&+HSDULQ+%30/0:+
4XDOLULV4&''LPHU
4XDOLULV4&/XSXV$QWLFRDJXODQW
4XDOLULV'LDJQRVWLF&KDOOHQJH
)RUIXWKHULQIRUPDWLRQSOHDVHUHIHUWR\RXUORFDOFRQWDFW
Auxiliary Reagents
"
Auxiliary Reagents

57
6ROXWLRQV
',"
- 89 D
YLDOVRI67$'HVRUE8
[PO
',
- 890 -0.

YLDOVRI67$&OHDQHU6ROXWLRQ
[O
*,
- 90 "4
YLDOVRI67$ &D&O0
[PO
*
- 89O1 900
YLDOVRI67$2ZUHQ.ROOHU%XIIHUS+
[PO
,'
H"P
YLDOVRI3(*
[PO
"""
528)2-0.
+
YLDOVRIZDVKLQJVROXWLRQIRU$VVHUDFKURP
[PO
7HVW&DUGV
""
?9
87

WHVWFDUGV
[
"%
??-
?07

WHVWFDUGV
[
"
$X[LOLDU\5HDJHQWV
Research Products
Research Products
Research Products Catalogue available on request

( Cat. Nr. 27935 )
"*
Research Kits

57
$FWLYLW\0HWKRGV
%&
-
50
8!;;9 ?
5HIHUWRSDJH
[PO
%"&
-
528#;;E# /@5
;;G
5HIHUWRSDJH
[PO
*
- 89-
528 ?;
5HIHUWRSDJH
WHVWV
'
- 8959=
&KURQRPHWULFGHWHUPLQDWLRQRI
SURFRDJXODQWSKRVSKROLSLGDFWLYLW\
YLDOVRISURFRDJXODQWSKRVSKROLSLG
GHSOHWHGSODVPD
YLDOVRI)DFWRU;D
YLDOVRI&RQWURO1
YLDOVRI&RQWURO3
[WHVWV
(/,6$0HWKRGV
528!;;
5HIHUWRSDJH
[WHVWV
'&
528!;;9
5HIHUWRSDJH
[WHVWV

528B
5HIHUWRSDJH
[WHVWV
%
528!;;;
5HIHUWRSDJH
[WHVWV
*&
528;!9;;
5HIHUWRSDJH
[WHVWV
*
528
5HIHUWRSDJH
[WHVWV
&%
528

5HIHUWRSDJH
[WHVWV
*&
528
0 ?;
5HIHUWRSDJH
[WHVWV
*
528? ?;
5HIHUWRSDJH
[WHVWV
*"
528
9
2;HM4
5HIHUWRSDJH
[WHVWV
,*
528H!
5HIHUWRSDJH
[WHVWV
*&*
528 ?;3 ?;
5HIHUWRSDJH
[WHVWV
9(.
=;-&*
4XDQWLWDWLYHGHWHUPLQDWLRQRIVROXEOH
&'
[FRDWHGVWULSV
WDEOHWVRI23'
[WHVWV
5HIHUWRSDJH
[PO
&
&

,PPXQR7XUELGLPHWULF0HWKRGV
"%&
=

89C
)ORZ&\WRPHWU\
0
0
H/;;3;;;O55./5+
5HIHUWRSDJH
VDPSOHV
"
0
0
;+
5HIHUWRSDJH
VDPSOHV
",
0
0
0
+
5HIHUWRSDJH
WHVWV
&%
0
0
H-5 +
5HIHUWRSDJH
WHVWV

4 F+
5HIHUWRSDJH
WHVWV
00>.
0
+
5HIHUWRSDJH
WHVWV
&
&&
&
5HVHDUFK3URGXFWV
",
Purified Proteins

57
*&
.A !)?
YLDO
"&'
.A ?
YLDO
"",
.A
2
YLDO
%'*
.A 2E#.G
YLDO
*
.A ?5
B
YLDO
'&
.A ?5
B
YLDO
%%%
.A ;;;
YLDO
*
.A # /@5

;;
YLDO
%%
.A
YLDO
'
.A N9H05
;
YLDO
'*
.A CK 2
YLDO
"%
5HVHDUFK3URGXFWV
Chromogenic Substrates & Activators

57
&KURPRJHQLF6XEVWUDWHV
%&&
C-&'E?5
BG
YLDO
%,
C-,E 2G
YLDO
$FWLYDWRUV
%
5
YLDO
%
9#.
YLDO
*&
!!
YLDO
" &

5
+
5HVHDUFK3URGXFW
YLDORI5LVWRFHWLQ
PJ
5HVHDUFK3URGXFWV
"'

57
$QWLSODWHOHWPDUNHUV
&
M50 CM/.@
PJ
& &
*M50 & "M/.@
PJ
&
*M50 & "M?;
WHVWV
&
*M50 & "M
WHVWV
& "
&M50 =9'M/.@
PJ
&
&M50 =9'M?;
WHVWV
& *
&M50 =9'M
WHVWV
& %
M50 =4&'M/.@
PJ
& ,
M50 =4&'M?;
WHVWV
& '
M50 =4&'M
WHVWV
& &
*&M50 =&%M/.@
PJ
&
*&M50 =&%M?;
WHVWV
&
*&M50 =&%M
WHVWV
& &,
*&M50 ?%M/.@
PJ
& &*
*&M50 ?%M?;
WHVWV
&
*M50 = M/.@
PJ
& &
*M50 = M?;
WHVWV
&
*M50 = M
WHVWV
&
? M50 '?'M?;
WHVWV
"
$QWLHQGRWKHOLDOFHOOPDUNHUV
&
*
&*M50 O4'M/.@
WHVWV
&
,
&*M50 O4?*M/.@
WHVWV
&
%
&*M50 O4"H*M/.@
WHVWV
& &&
&*M50 O4,M/.@
WHVWV
& &
&*M50 O4,M?;
WHVWV
&
&*M50 O4,MC

WHVWV
& &
&*M50 -9O&M/.@
WHVWV
& &
&*M50 -9O&M?;
WHVWV
& &"
&*M50 -9O&M
WHVWV
& &
&*M50 -9O&MC

WHVWV
'
5HVHDUFK3URGXFWV

57
,VRW\SLF1HJDWLYH&RQWUROV
& &'

0 ;H&/.@E#&&G
PJ
& &%

0 ;H&9?; E#&&G
WHVWV
&

0 ;H&9E#&&G
WHVWV
& %

0 ;H/.@E&*&G
PJ
& ,

0 ;H9?; E&*&G
WHVWV
& '

0 ;H9E&*&G
WHVWV
& "

0 ;H/.@E&H"G
PJ
&

0 ;H9?; E&H"G
WHVWV
& *

0 ;H9E&H"G
WHVWV
5HVHDUFK3URGXFWV
*&
Thrombin Generation (CAT)*

57
%*&'
20

YLDOVRIPO
[PO
%*&'*

YLDOVRIPO
[PO
%*
4

YLDOVRIPO
[PO
%*&'

YLDOVRIPO
[PO
%*&'
9
=O)
YLDOVRIPO
[PO
%*&'"
9
#;H#
YLDOVRIPO
[PO
%*&',
?0.7

YLDOVRIEXIIHU
YLDORIVXEVWUDWH
*
5HVHDUFK3URGXFWV

Disposables
Disposables &
Auxiliary materials
STA-R / STA-R Evolution Expert Series Disposables

57
6ROXWLRQV
',"
- 89 D
YLDOVRI67$'HVRUE8
[PO
',
- 890 -0.

[O
UROOVRI67$&XYHWWHV
[
'LVSRVDEOHV
%**'
- 89.K
%
- 89455./
0LFURWXEHVLQVLOLFRQHGJODVVIRUUHDJHQWV ER[RI67$0LFURFXSV
FRQWURODQGFDOLEUDWLRQSODPDV
[
,&
- 89455

3ODVWLFFXSVIRUVDPSOHV
ER[RI67$0LFURFRQWDLQHU
[
,'*
- 89/
2SHUFXODWHFDSV',1IRUDQLPSURYHG
VWDELOLW\
ER[RI67$&DSV
[
,',
- 894 .5
3ODVWLFFKLPQH\V',1IRUFKURPRJHQLF
UHDJHQWVLPSURYHGVWDELOLW\
ER[RI67$0LQL5HGXFHU
[
% &
- 894F .5
ER[RI67$0D[L5HGXFHU
[
,*
- 8945 .5
3ODVWLFFKLPQH\V',1IRU4&PDWHULDO
LPSURYHGVWDELOLW\
ER[RI67$0LFUR5HGXFHU
[
,"
)2

IRU67$1pRSODVWLQH
LWHP

**,

IRU67$&.3UHVW
LWHP

*
'LVSRVDEOHV DX[LOLDU\PDWHULDOV
STA-R / STA-R Evolution Expert Series Disposables Spare Parts

57
'&*
0 &@5// 5
LWHP

''
0 &
LWHP

'"
0
LWHP

, ,
0
LWHP

,"
Q
/@ 9
LWHP
[
**''
#0 0/
LWHP

,"%
=>.A0

LWHP

',%
=>.A0

LWHP

,"%
#0
9
LWHP

'&*
-.5
2 E!G
LWHPV

%, *
-.5
2 E!"G
LWHPV

%"&,
A0
E"'F&",G
LWHP

'%%
"F &@.
IXVHV

**%
"F @.
IXVHV

**%
"F "@.
IXVHV

**%&
"F *@.
IXVHV

'%*
"F & @.
IXVHV

,",*
*F @.
IXVHV

,",%
*F "@.
IXVHV

,","
*F *"@.
IXVHV

**'
*F &"@.
IXVHV

%&"
0
5FA0
!
LWHP

'&
)2 0@
.

LWHPV

%
-@

0
7
E& G
LWHPV

*"
STA-R / STA-R Evolution Expert Series Auxiliary Materials

57
*"""
C00 F
5

LWHP

''*%
455.//

LWHPV

'
0..55
/

E5K0. G
LWHPV

%%" '
1-
/

LWHPV
' &
-/0

LWHPV

%,,,
-/0 5720 E@"57G
LWHP

',,
-/0 5720 E@"57G
LWHPV

'&,
-/0 57E"57G
LWHP

''&%

557E57G
LWHP

% '&'
.F0F- 98// 5
LWHP

% '&%
.F0F- 98
LWHP

'&
4 O0
5-/ !'
LWHP

% "
0 @5 M7 /

LWHP

%
455
57EG
LWHPV

**
STA Compact Max / STA Compact USB & STA Compact CT USB Disposables

57
6ROXWLRQV
',"
- 89 D
YLDOVRI67$'HVRUE8
[PO
',
- 890 -0.

[O
- 89.K
UROOVRI67$&XYHWWHV
[
%
- 89455./
0LFURWXEHVLQVLOLFRQHGJODVVIRUUHDJHQWV
FRQWURODQGFDOLEUDWLRQSODPDV
ER[RI67$0LFURFXSV
[
,&
- 89455

[
,'*
- 89/
VWDELOLW\
ER[RI67$&DSV
[
,',
- 894 .5
ER[RI67$0LQL5HGXFHU
[
% &
- 894F .5
ER[RI67$0D[L5HGXFHU
[
,*
- 8945 .5
3ODVWLFFKLPQH\V',1IRU4&PDWHULDO
LPSURYHGVWDELOLW\
ER[RI67$0LFUR5HGXFHU
[
,"
)2

IRU67$1pRSODVWLQH
LWHP

**,

IRU67$&.3UHVW
LWHP

'LVSRVDEOHV
%**'
*,
STA Compact Max / STA Compact USB & STA Compact CT USB
Disposable Spare Parts

57
%**
0 &
!
LWHP

,"
0
LWHP

, ,
0
LWHP

'
0 &@5// 5!
LWHP

,"
Q
/@ 9
[LWHPV

,"%
=>.A0

LWHP

',%
=>.A0

LWHPV

**''
#0 0/+
LWHP

,"%
#0
9
LWHP

,&
-.5
2
LWHPV

,
A0

LWHPV

,",
/0
A0

LWHP

*"%
0
5FA0
+
LWHP

%&"
0
5FA0
!+
LWHP

,
*F @.
IXVHV

,",'
*F &@.
IXVHV

, ,
*F @.
IXVHV

,","
*F *"@.
IXVHV

,"
*F %@.
IXVHV

,
*F & @.
IXVHV

%"%&
.!/ 5
LWHPV

%*
=>.0H050
LWHP
O
%
-@

0
7
E& G
LWHPV

*%
)RU67$&RPSDFW0D[DQG67$&RPSDFWRQO\
STA Compact Max / STA Compact USB & STA Compact CT USB
Auxiliary Materials

57
*"""
C00 F
5

LWHP

''*%
455.//

LWHPV

,
45
/
E5K0. G
LWHPV

* &
7
LWHP

,"&*
() 7
LWHP

// 57
!
LWHP

,
*'
STA Satellite Disposables*

57
6ROXWLRQV
',"
- 89 D
YLDOVRI67$'HVRUE8
[PO
',
- 890 -0.

[O
'LVSRVDEOHV
'
- -
00
8.K
UROOVRI67$6DWHOOLWH&XYHWWHV
[
,"
)2

IRU67$1pRSODVWLQH
LWHP

,&
- 89455

[
%
- 89455./
0LFURWXEHVLQVLOLFRQHGJODVVIRUUHDJHQWV ER[RI67$0LFURFXSV
FRQWURODQGFDOLEUDWLRQSODVPDV
[
,'*
- 89/
VWDELOLW\
ER[RI67$&DSV
[
,',
- 894 .5
ER[RI67$0LQL5HGXFHU
[
% &
- 894F .5
ER[RI67$0D[L5HGXFHU
[
**'
2 0//

'LVSRVDEOHV6SDUH3DUWV
**%&
"F *@.
IXVHV

% &
A0

LWHPV

STA Satellite Auxiliary Materials*

57
*"""
C00 F
5

LWHP

'"'
.5
E;&G
LWHPV

''*%
455.//

LWHPV

.5 @5K0. /0
LWHPV

",
,&
Semi-Automated Analysers Disposables

57
VWULSVRIFXYHWWHV

YLDORIEDOOV

67DUW
%%,*
-
85.K

67DUW67DUW67DOLD
*&
C00K0
**'
2 0//
% "&
?
/8"0E/
&R" T0G
ER[RI)LQQWLSV

% "
?
/8&"0E/
&R"T0G
ER[RI)LQQWLSV

IXVHV

'LVSRVDEOHV6SDUH3DUWV
,"%&
,
-0101@. *F
Semi-Automated Analysers Auxiliary Materials

57
67DUW 67DUW 67DOLD
% & '
0 5
500907 //

*"""
C00 F
5

',*
C00/

*,'
.5
@"0
.

* "
4
5
E*F&G+

** "
.5
E;&G

**&
.5
E;&%G

% '

5
K

)RU67DUWDQG67DUWRQO\
,
CAT Disposables*

57
PLFURWLWHUSODWHV
[
&$7'LVSRVDEOHV
%*&,"
;.0#C0

'LVSRVDEOHVSDUHSDUWV
%*&,,
#0 =/
XQLW
%*&%"
/0
/
.
XQLW
%*&%

.
XQLW
%*&,*
/
/
XQLW
,
Index
A
Asserachrom Anti-Prothrombin IgG, M ....................................................... 42-57
Asserachrom Anti-2 GPI IgG ........................................................................... 42
Asserachrom Anti-2 GPI IgM .......................................................................... 42
Asserachrom APA IgG, M................................................................................... 42
Asserachrom APA Screen ................................................................................... 42
Asserachrom D-Di ............................................................................................. 29
Asserachrom Free Protein S .............................................................................. 39
Asserachrom Free TFPI ............................................................................... 40-57
Asserachrom HPIA............................................................................................. 34
Asserachrom HPIA - IgG ................................................................................... 34
Asserachrom IX:Ag............................................................................................. 25
Asserachrom PAI-1............................................................................................ 32
Asserachrom PF4 .............................................................................................. 44
Asserachrom PIVKA-II ................................................................................. 25-57
Asserachrom Protein C ...................................................................................... 38
Asserachrom Protein Z................................................................................. 40-57
Asserachrom sEPCR .................................................................................... 40-57
Asserachrom sGPV ...................................................................................... 44-57
Asserachrom -TG ............................................................................................. 44
Asserachrom TAFIa/TAFIai .......................................................................... 32-57
Asserachrom Total Protein S ............................................................................. 39
Asserachrom Total TFPI ............................................................................... 40-57
Asserachrom tPA ............................................................................................... 32
Asserachrom VII:Ag ..................................................................................... 25-57
Asserachrom VIIa-AT ................................................................................... 25-57
Asserachrom VIII:Ag .................................................................................... 25-57
Asserachrom VWF:Ag ........................................................................................ 44
Asserachrom VWF:CB ....................................................................................... 44
Asserachrom VWF:FVIIIB ............................................................................ 25-44
Asserachrom Washing Solution......................................................................... 54
Asserachrom X:Ag ........................................................................................ 25-57
C
C.K. Prest 2 ....................................................................................................... 19
C.K. Prest 5 ....................................................................................................... 19
Cap piercing kit V3............................................................................................... 71
CAT disposables ................................................................................................... 74
CAT System QWERTY .......................................................................................... 12
CBS 31.39 (Factor Xa) ........................................................................................ 59
CBS 34.47 (Thrombin)........................................................................................ 59
Cellquant Calibrator ....................................................................................... 45-57
Cellquant PNH .................................................................................................... 45
Coag Control N+P ............................................................................................... 51
Coag-Norm........................................................................................................ 51
Coag-Path ......................................................................................................... 51
Cy-Quant ELISA sCD146 ..................................................................................... 57
D
D-Di Test............................................................................................................ 29
E
ECA - H ................................................................................................................ 36
ECA - H controls ............................................................................................ 33-51
ECA - T ................................................................................................................. 36
ECA - T controls argatroban........................................................................... 36-51
ECA - T controls bivalirudin ........................................................................... 36-51
ECA - T standards argatroban ........................................................................ 36-50
ECA - T standards bivalirudin ......................................................................... 36-50
Ecarin................................................................................................................... 59
Etaloquick .......................................................................................................... 50
F
F.S. Test ............................................................................................................... 28
F.S. Test Unit........................................................................................................ 28
Factor XIII Reagents ...................................................................................... 25-28
FDP Plasma......................................................................................................... 29
FDP Plasma (Buffer) ........................................................................................... 29
FDP Plasma (Latex) ............................................................................................ 29
Fibrinogen, clone 9F9, FITC.......................................................................... 46-60
Fibri-Prest Automate 2 ...................................................................................... 20
Fibri-Prest Automate 5 ...................................................................................... 20
Finntips 1.25 ml (position 1 = 25 l) ............................................................... 74
Finntips 2.5 ml (position 1 = 50 l).................................................................. 74
FluCa kit .............................................................................................................. 62
I
Immulon 2HB Plate ............................................................................................ 74
L
Liatest AT III ....................................................................................................... 38
Liatest C4b-BP ............................................................................................ 39-57
M
Megamix ........................................................................................................ 45-57
Monoclonal Antibodies For Flow Cytometry ................................................. 60-61
MP Reagent ......................................................................................................... 62
N
Noplastine CI 5 ................................................................................................ 18
Noplastine CI 10 ............................................................................................. 18
Noplastine CI Plus 2 ........................................................................................ 18
Noplastine CI Plus 5 ........................................................................................ 18
Noplastine CI Plus 10 ..................................................................................... 18
P
PEG 25% ............................................................................................................. 54
Platelet Calibrator .......................................................................................... 45-57
Platelet GP Screen ........................................................................................ 45-57
Platelet GpIIb/IIIa Occupancy ....................................................................... 45-57
Platelet PAIg .................................................................................................. 45-57
PLT GP Receptors ................................................................................................ 45
PLT HPA-1........................................................................................................... 45
PLT VASP/P2Y12................................................................................................. 45
Pool Norm ..................................................................................................... 19-41
PPP Reagent ....................................................................................................... 62
PPP-Reagent HIGH ............................................................................................ 62
PPP-Reagent LOW .............................................................................................. 62
Protective bag...................................................................................................... 73
PTT-LA ........................................................................................................... 19-41
PTT Automate 10 ................................................................................................ 19
PTT Automate 5................................................................................................... 19
PRP Reagent ....................................................................................................... 62
Puried APC......................................................................................................... 58
Puried AT III ....................................................................................................... 58
Puried Bovine Thrombin .................................................................................... 58
Puried Factor X .................................................................................................. 58
Puried Factor Xa ................................................................................................ 58
Puried Fibrinogen .............................................................................................. 58
Puried Heparin Cofactor II ................................................................................. 58
Puried Prothrombin ........................................................................................... 58
Puried 2-GlycoProtein I................................................................................... 58
Puried Thrombin (Human) ................................................................................ 58
Puried VWF........................................................................................................ 58
Q
Qualiris by Stago.................................................................................................. 51
R
R.V.V. .................................................................................................................... 59
Redquant PNH .................................................................................................... 45
r-Hirudin .............................................................................................................. 59
S
SPA 20................................................................................................................. 18
STA Compact Max AZERTY ...................................................................................7
STA Compact Max AZERTY Cap Piercing..............................................................7
STA Compact Max AZERTY Cap Piercing Expert Module .....................................7
STA Compact Max AZERTY Expert Module ..........................................................7
STA Compact Max QWERTY.................................................................................7
STA Compact Max QWERTY Cap Piercing ...........................................................7
STA Compact Max QWERTY Cap Piercing Expert Module ...................................7
STA Compact Max QWERTY Expert Module ........................................................7
STA Compact USB ................................................................................................8
STA Compact CT USB ...........................................................................................9
STA Compact USB equipped with cap piercing ....................................................8
STA Satellite ...................................................................................................... 10
STA Satellite Cuvettes........................................................................................ 70
STA-R Evolution Expert Series..............................................................................6
STA-R Evolution Expert Series equipped with cap piercing ..................................6
STart4 (115V/230V) ......................................................................................... 11
STA-C.K. Prest 5.............................................................................................. 19
STA-CaCl2 0.025 M .......................................................................................... 54
STA-Caps ............................................................................................... 64-67-70
STA-Cephascreen 4 ......................................................................................... 19
STA-Cephascreen 10 ....................................................................................... 19
STA-Cleaner Solution ............................................................................ 54-64-67
STA-Coag Control N+P ..................................................................................... 51
STA-Control LA 1 + 2 ........................................................................................ 51
,"
Index
STA-Cuvettes ............................................................................................... 64-67
STA-Decient II.................................................................................................. 24
STA-Decient V.................................................................................................. 24
STA-Decient VII ............................................................................................... 24
STA-Decient VIII .............................................................................................. 24
STA-Decient IX................................................................................................. 24
STA-Decient X .................................................................................................. 24
STA-Decient XI................................................................................................. 24
STA-Desorb U .................................................................................. 54-64-67-70
STA-FDP Calibrator ........................................................................................... 50
STA-FDP Control ............................................................................................... 51
STA-Fib 2........................................................................................................... 20
STA-Fibrinogen 5 .............................................................................................. 20
STA-FM Calibrator ............................................................................................. 50
STA-FM Control ................................................................................................ 51
STA-Fondaparinux Calibrator............................................................................. 50
STA-Fondaparinux Control ................................................................................ 51
STA-HBPM/LMWH Control .............................................................................. 51
STA-Hepanorm H ............................................................................................ 50
STA-Hepanorm HBPM/LMWH....................................................................... 50
STA-Heparin Control ......................................................................................... 51
STA-ImmunoDef II ............................................................................................ 24
STA-ImmunoDef VIII ......................................................................................... 24
STA-ImmunoDef IX............................................................................................ 24
STA-ImmunoDef XII .......................................................................................... 24
STA-Liatest Control N+P ................................................................................. 51
STA-Liatest D-Di.............................................................................................. 29
STA-Liatest FM ................................................................................................ 28
STA-Liatest Free Protein S 2 ........................................................................... 39
STA-Liatest Free Protein S 6 ........................................................................... 39
STA-Liatest VWF:Ag ........................................................................................ 44
STA-Liatest FDP .............................................................................................. 29
STA-Liquid Anti-Xa 4 ......................................................................................... 34
STA-Liquid Anti-Xa 8 ......................................................................................... 34
STA-Liquid Fib ................................................................................................... 20
STA-Multi Hep Calibrator .................................................................................. 50
STA-Noplastine CI 5 ...................................................................................... 18
STA-Noplastine CI 10 .................................................................................... 18
STA-Noplastine CI Plus 5 .............................................................................. 18
STA-Noplastine CI Plus 10 ............................................................................ 18
STA-Noplastine R 15 ..................................................................................... 18
STA-Owren-Koller ............................................................................................. 54
STA-Procoag-PPL.............................................................................................. 57
STA-PTT Automate 5 ......................................................................................... 19
STA-Quality HBPM/LMWH .............................................................................. 51
STA-Quality HNF/UFH...................................................................................... 51
STA-Reptilase .................................................................................................. 21
STA-Rivaroxaban Calibrator ............................................................................... 50
STA-Rivaroxaban Control .................................................................................. 51
STA-Routine QC 2 ml ........................................................................................ 51
STA-Routine QC P Plus ..................................................................................... 51
STA-Scandinorm ................................................................................................ 51
STA-Scandipath ................................................................................................. 51
STA-SPA+ .......................................................................................................... 18
STA-Stachrom Antiplasmin .............................................................................. 32
STA-Stachrom AT III 3 ..................................................................................... 38
STA-Stachrom AT III 6 ..................................................................................... 38
STA-Stachrom Plasminogen............................................................................ 32
STA-Stachrom Protein C.................................................................................. 38
STA-Stachrom TAFI ................................................................................... 32-57
STA-Staclot APC-R .......................................................................................... 38
STA-Staclot DRVV Conrm .............................................................................. 41
STA-Staclot DRVV Screen 2 ............................................................................ 41
STA-Staclot DRVV Screen 5 ............................................................................ 41
STA-Staclot Heparin 1 ..................................................................................... 34
STA-Staclot Protein C ...................................................................................... 38
STA-Staclot Protein S ...................................................................................... 39
STA-System Control N+P .................................................................................. 51
STA-Systems Disposables.......................................................... 64-67-70-72-74
STA-Systems Spare Parts ............................................................................ 67-70
STA-Systems Auxiliary Materials...................................................... 66-69-71-73
STA-Thrombin 2 ................................................................................................ 21
STA-Thrombin 10 .............................................................................................. 21
STA-Unicalibrator .............................................................................................. 50
STA-VWF:Ag Calibrator ..................................................................................... 50
Stachrom HCII (Heparin Cofactor II) ........................................................... 40-57
Stachrom Heparin ............................................................................................. 34
Stachrom PAI .................................................................................................... 32
Staclot LA .......................................................................................................... 41
,*
Staclot VIIa-rTF ........................................................................................... 25-57

STic Expert HIT 20 ............................................................................................ 34
STic Expert HIT 5............................................................................................... 34
System Control N+P............................................................................................ 51
T
Test cards for D-Di Test kit ................................................................................... 29
Test cards for F.S. Test and FDP Plasma kits ................................................. 28-29
Thrombin Calibrator............................................................................................. 62
U
Unicalibrator ........................................................................................................ 50
Notes
,,
Notes
,%
,'
agenceL2R.com - 2009 DIAGNOSTICA STAGO - All rights reserved - Non-contractual photos - 01/2013 - Ref. 27866 - Printed on PEFC paper

Cat Stago International en - BD Eb

Transféré par

Informations du document

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

Cat Stago International en - BD Eb

Transféré par

Droits d'auteur :

Formats disponibles

Haemostasis Catalogue

STA-R Evolution Expert Series System ....................................................................................................................................................................6

Decient Plasmas ....................................................................................................................................................................................................24

Fibrin Formation & Degradation

Fibrin Formation ......................................................................................................................................................................................................28

Heparins & Direct Anti-Xa ........................................................................................................................................................................................34

Antithrombin & Protein C.........................................................................................................................................................................................38

Von Willebrand Factor & Activation Markers ...........................................................................................................................................................44

Calibrators & Controls

Calibration Plasmas .................................................................................................................................................................................................50

Auxiliary Reagents ...................................................................................................................................................................................................54

Research Kits ...........................................................................................................................................................................................................57

Disposables & Auxiliary materials

STA-R / STA-R Evolution Expert Series Disposables ...........................................................................................................................................64

The information contained in this catalogue are not contractual

STA-R Evolution Expert Series System

   !" #$

()  &&"!* #$

()   !* #$

()   !" #$

STA Compact Max System

()  &&"3 !

  &&"3 !

STA Compact USB System

  &&"3 !

()  &&"3 !

STA Compact CT USB System

  &&"3 !

()  &&"3 !

STA Satellite System

STA Coag Connexion System

- 89 /2 5 8

- 89 /2 5 8&

Fibrin Formation & Degradation

?0 EC.@@ G

 528 ?;3 ?;

Heparins & Direct Anti-Xa

Heparins & Direct Anti-Xa

Direct Thrombin Inhibitors

Antithrombin & Protein C

Protein S & C4b-Binding Protein

Lupus Anticoagulant (LA)

Antiphospholipid Antibodies (APA)

Von Willebrand Factor & Activation Markers

Monoclonal Antibodies For Flow Cytometry*

*M50 & "M/.@

*M50 & "M?; 

*M50 & "M

*M50 = M/.@

*M50 = M?; 

*M50 = M

? M50 '?'M?; 

Monoclonal Antibodies For Flow Cytometry*

Calibrators & Controls

Research Products Catalogue available on request

 528 ?;3 ?;

.A  ;;;

.A # /@5

.A CK  2

Chromogenic Substrates & Activators

Monoclonal Antibodies For Flow Cytometry*

*M50 & "M/.@

*M50 & "M?; 

*M50 & "M

!" #$

() &&"!* #$

() !* #$

() !" #$

() &&"3 !

&&"3 !

&&"3 !

() &&"3 !

&&"3 !

() &&"3 !

- 89 /25 8

- 89 /25 8&

?0EC.@@ G

528 ?;3 ?;

*M50 & "M/.@

*M50 & "M?;

*M50 & "M

*M50 = M/.@

*M50 = M?;

*M50 = M

? M50 '?'M?;

528 ?;3 ?;

.A ;;;

.A # /@5

.A CK 2

*M50 & "M/.@

*M50 & "M?;

*M50 & "M

*M50 = M/.@

*M50 = M?;

*M50 = M

? M50 '?'M?;

"F & @.

-/0 5720 E@"57G

-/0 5720 E@"57G

.F0F- 98// 5

0 @5 M7 /

*F & @.

7

() 7

.5 @5K0. /0

67DUW 67DUW 67DOLD